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CHAPTER I 
I N T R O D U C T I O N A N D O U T L I N E O F I N V E S T I G A T I O N S 
INTRODUCTION 
Triglycerides are transported in the plasma in two classes of triglyceride-rich 
lipoproteins: chylomicrons and very low density lipoproteins (VLDL). In this 
thesis studies will be described concerning various forms of hypertriglycerid­
emia, caused by elevations of plasma VLDL and/or chylomicrons. For a 
better understanding of these studies the metabolism of plasma lipoproteins 
will be discussed briefly in this chapter. For more detailed information the 
reader may be referred to several excellent reviews on this subject, which 
have been published recently.1"6 
Chylomicrons carry triglycerides from exogenous origin (dietary fat); they 
are secreted from the absorptive cells into the lymph and subsequently enter 
the plasma via the thoracic duct. VLDL are synthesized mainly in the liver 
and to a lesser extent in the intestine and transport triglycerides from 
endogenous sources.1-3 The main precursors for triglycerides in VLDL are 
plasma free fatty acids, which are esterified with α-glycerophosphate. In the 
liver fatty acids can also be synthesized from carbohydrates.7 The chylomi­
crons are huge macromolecular complexes which contain a higher amount of 
triglyceride than the smaller VLDL particles (85% and 55% of dry mass, 
respectively).1 The structure of the lipoprotein macromolecular complexes is 
well suited for the solubilization of lipids in the plasma. The hydrophobic 
lipids are packaged in the lipoprotein core, surrounded by a surface mono­
layer composed of phospholipids, unesterified cholesterol and specific pro­
teins, called apo(lipo)proteins.1·2 The triglyceride-rich lipoproteins are 
hydrolyzed in the circulation by extrahepatic lipoprotein lipase, an enzyme 
that is present at the luminal surface of the capillary endothelial cells of 
muscle and adipose tissue. This enzyme is activated by an apoprotein present 
at the surface of the triglyceride-rich lipoproteins, apoC-II. The enzyme can 
be measured in tissue biopsies or after release from the endothelial cells into 
the plasma by an intravenous injection of heparin. A second lipase from 
hepatic origin is also released into the plasma by heparin. Monoglycerides 
and free fatty acids, which are liberated from the triglyceride-rich lipopro­
teins by the interaction with lipoprotein lipase, enter the adjacent muscle or 
adipose cells where they are either oxidized for energy or re-esterified to 
triglycerides for storage.1 As the triglyceride core is stepwise depleted, the 
lipoprotein particle decreases in size and increases in density. The excess 
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surface material, phospholipids, cholesterol and apoproteins, is transferred to 
another lipoprotein, high density lipoprotein (HDL), where cholesterol can 
be esterified.8·9 The lipoprotein particles are thus converted into chylomicron 
remnants and VLDL remnants, also called intermediate density lipoproteins 
(IDL). The interaction of chylomicrons with lipoprotein lipase is very 
efficient as becomes apparent from their half-life of about 5 minutes, whereas 
that of VLDL is several hours. The chylomicron remnants are transported to 
the liver, where they bind to receptors on the surface of hepatocytes and are 
internalized and degraded.1 0 , 1 1 VLDL remnants, in which most of the original 
triglyceride core is replaced during lipolysis by cholesterol esters transferred 
from HDL, are further converted into low density lipoproteins (LDL). This 
conversion occurs probably in the liver. Some of the VLDL remnants are 
catabolized directly by the liver.12 The LDL particle contains mainly choles­
terol esters in the core and apoprotein В at the surface. This apoprotein В is 
an important structural protein of chylomicrons, VLDL, IDL and LDL and 
remains quantitatively conserved per particle throughout the catabolic 
cascade from VLDL -» IDL -> LDL. 1 2 1 3 LDL delivers cholesterol to the 
peripheral cells after binding to high affinity receptors at the plasma mem­
brane. LDL is also degraded by a less efficient mechanism called "scavenger 
pathway".6 
It has been suggested that HDL removes cholesterol from peripheral cells 
and carries it to the liver for excretion.9 1 5 Cholesterol that binds to HDL is 
esterified with fatty acids from lecithin by the enzyme lecithin-cholesterol 
acyltransferase. Thus, the metabolism of VLDL, LDL and HDL appears to 
be closely interrelated. 
Apoproteins 
Knowledge of the structure and function of apoproteins has increased rapidly 
during the last several years. The apoproteins have not only a function at the 
surface of the lipoproteins for solubilization but a number of physiological 
functions in addition. This is illustrated best by rare inborn errors of 
metabolism, which are characterized by a virtual absence of one or more 
apoproteins leading to severe disturbances in lipoprotein metabolism. For 
instance, subjects with abetalipoproteinemia lack apoprotein В and no 
chylomicrons, VLDL and LDL can be formed; these subjects have severe fat 
malabsorption and neurological symptoms and die mostly before the end of 
the second decade of life.2 In Tangier disease there is a deficiency of the 
apoproteins A-I and A-II, which are indispensable for the structure of HDL 
particles; in these patients cholesterol esters are deposited in the reticuloen­
dothelial cells, in particular in tonsils, liver and spleen.1 In 1978, the first 
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Table 1. Distribution, approximate molecular weight and concentration In plasma and 
function of the major human plasma apollpoprotelns.1,5 
Apolipoprotein 
apoA-I 
apoA-Il 
apoB 
apoC-I 
apoC-II 
apoC-III 
apoD 
apoE 
Lipoprotein class 
HDL 
HDL 
Chyl, VLDL, 
IDL, LDL 
Chyl, VLDL, 
HDL 
HDL 
Chyl, VLDL. 
IDL, HDL 
Molecular 
weight 
28.000 
17.000 
250.000 
6.000 
9.000 
9.000 
22.000 
33.000 
Approximate 
concentration 
(g/i) 
1.3 
0.4 
0.8 
0.06 
0.03 
0.12 
0.10 
0.05 
Function 
cofactor of lecithin-cholesterol 
acyltransferase 
? 
lipoprotein transpon; 
binding to cell receptor 
? cofactor LPL 
cofactor LPL 
? inhibits LPL and binding to cell 
receptor 
cholesterol ester exchange protein 
binding to cell receptor 
patient was described with a deficiency of apoC-II, the specific activator of 
lipoprotein lipase, resulting in gross hypertriglyceridemia.16 Type III hyperli-
poproteinemia is characterized by a deficiency of apoE-3 and apoE-4, which 
are involved in the recognition and uptake of remnants by liver cell recep-
tors 11.17 
The major human apoproteins, their distribution in the lipoprotein classes 
and approximate molecular weight and plasma concentration are summari-
zed in table 1. 
Hypertriglyceridemia 
By far the commonest of the primary hypertriglyceridemic states is due to 
elevated VLDL levels, designated as type IV hyperlipoproteinemia in the 
classification system of Frederickson et al.19 Hypertriglyceridemia due to 
chylomicronemia (type I hyperlipoproteinemia) is a clinically and biochemi-
cally distinct rare disorder.1 In some patients with hypertriglyceridemia, 
plasma lipoprotein analysis reveals an excess of both VLDL and chylomi-
crons (type V hyperlipoproteinemia). In these cases the hypertriglyceridemia 
is usually very severe. 
Secondary hypertriglyceridemia (mostly due to elevated VLDL levels) can 
be found in diabetes mellitus, alcoholism and a number of other conditions. 
Disorders associated with hypertriglyceridemia are summarized in table 2. 
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Table 2. Hypertriglycerldemlc disorders.' 
Genene designaüon 
(elevated lipoprotein 
class) 
Classification 
by Frednckson Primary disorders 
et al" 
Secondary disorders 
Exogenous hyperlipemia 
(chylomicrons) 
Endogenous hyperlipemia 
(VLDL) 
Mixed hyperlipemia 
(chylomicrons + VLDL) 
Type I Familial LPL deficiency 
Familial apoC-II deficiency 
Type IV Familial hypertnglycendemia 
Familial combined hyper-
hpidemia 
Sporadic hypertnglycendemia 
Tangier disease 
Type V Familial hypertriglyceridemia 
(severe form) 
Dysglobulinemia 
Systemic lupus erythematosis 
' Diabetes mellitus 
Alcoholism 
Estrogen use 
Glucocorticoid use 
I Pregnancy 
f Uremia 
Pancreatitis 
I Hypothyroidism 
I Nephrotic syndrome 
Glycogenosis, type I 
Lipodystrophies 
Dysglobulmemias 
V Stress-induced 
Type I and type V hyperlipoproteinemia are frequently accompanied by 
episodic abdominal pain, pancreatitis, eruptive xanthomas, lipemia retinalis 
and hepatosplenomegaly. Pancreatitis is sometimes a fatal complication, 
especially in type I hyperlipoproteinemia.1·2 
Type IV hyperlipoproteinemia is very common in the western countries. 
Lewis et al20 reported that 14% of men and 3.6% of women aged 20-69 years 
had elevated fasting triglyceride levels (plasma triglyceride > 2.0 mmol/1). 
Similar figures have been reported by others.21,22 So, there is a clear male 
preponderance in subjects with hypertriglyceridemia. Interest in type IV 
hyperlipoproteinemia stems from its frequent association with premature 
vascular disease.23 However, the role of hypertriglyceridemia in early deve-
lopment of atherosclerosis is less well defined than that of hypercholesterol-
emia. Although in two prospective Scandinavian studies elevated triglyceride 
levels have been reported to be an independent risk factor,24"26 this has not 
been confirmed by others.27"29 By multivariate analysis, including HDL-
cholesterol, plasma triglyceride does not appear to be an independent risk 
factor.27-28 Its risk seems to be derived from secondary associations with 
atherosclerosis such as the negative correlation with HDL-cholesterol. In 
several prospective studies plasma HDL-cholesterol is inversely correlated 
with the risk of cardiovascular disease.27,28·30 On the other hand, hypertrigly-
ceridemia may be associated with premature atherosclerosis in some specific 
disorders that may not be apparent in studies of whole populations, such as in 
familial forms of hypertriglyceridemia.31 In addition, elevated VLDL levels 
may increase the risk for premature atherosclerosis when associated with 
other risk factors such as diabetes, hypertension, smoking and uremia. 
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OUTLINE OF INVESTIGATIONS 
In this thesis we describe studies to elucidate the pathophysiological defects 
in various forms of hypertriglyceridemia, including type I, type IV and type V 
hyperlipoproteinemia. Special attention was given to the possibilities of an 
increased production rate of plasma triglyceride on one hand, and a decrea-
sed removal on the other. For that purpose, the turnover rate of plasma 
triglyceride, the activity of lipoprotein lipase and the composition of the 
apoproteins of the substrate for lipoprotein lipase, VLDL and/or chylomi-
crons, were determined. 
Several methods have been described in the literature to measure plasma 
triglyceride turnover rate. All these methods are based on certain assump-
tions which have not been completely validated. These methods are discus-
sed in chapter II as well as the procedure and validation of the method with 
radioglycerol which we have used in our studies. The plasma triglyceride 
turnover rate was studied in normal subjects and in a large number of 
subjects with primary and secondary type IV hyperlipoproteinemia. 
Two distinct monogenetic forms of hypertriglyceridemia have been recogni-
zed: familial hypertriglyceridemia (FHT) with affected family members who 
have only elevated VLDL levels and familial combined hyperlipidemia 
(FCH) with affected family members who may have a rise in plasma VLDL 
(type IV phenotype), plasma LDL (type IIa phenotype) or both lipoproteins 
(type lib phenotype).31 Subjects with elevated VLDL levels from families 
with FCH appear to have an increased risk of cardiovascular disease.32 We 
describe in chapter III a study of genetically well defined subjects with type 
IV hyperlipoproteinemia in an attempt to distinguish FHT from FCH and to 
find metabolic differences which could explain the difference in risk. 
The pathogenetic mechanism of hypertriglyceridemia secondary to maturity-
onset diabetes has been a subject of controversy: both increased production 
and impaired removal of plasma triglyceride have been claimed to be the 
underlying defect. We have investigated the pathogenetic defects in non-
insulin-dependent diabetic subjects with hypertriglyceridemia in relation 
with plasma glucose and insulin levels. The influence of diabetic control on 
plasma HDL-cholesterol was also studied. For that purpose, we measured 
plasma triglyceride turnover rate and lipolytic activities, glucose and insulin 
concentrations in 26 patients with maturity-onset diabetes and hypertriglyce-
ridemia (chapter IV). Because diabetic control in these patients is frequently 
poor despite treatment with diet alone or hypoglycemic agents in addition, 
we have treated these subjects with insulin and studied the effects on several 
metabolic variables. The aim of this study was also to see, whether a 
favorable effect on plasma lipoproteins would provide an additional reason 
to treat these patients with insulin. 
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The VLDL-apoC composition was determined in subjects with maturity-
onset diabetes and hypertriglyceridemia in search for a possible role of an 
abnormal apoC composition in the pathogenesis of hypertriglyceridemia in 
these subjects (chapter V). 
In chapter VI we describe two patients with severe hypertriglyceridemia 
(type V) secondary to alcohol abuse and diabetes mellitus. The role of 
lipoprotein lipase and of apoprotein С and E composition of the triglyceride-
rich lipoproteins before and during the rapid changes in the lipoproteins was 
investigated. 
In chapter VII we describe the underlying defect in four siblings with familial 
hyperchylomicronemia (type I hyperlipoproteinemia). In these subjects a 
combined deficiency of apoprotein C-II and lipoprotein lipase was demon­
strated. The effect of an infusion of normal plasma, containing the missing 
activator factor, was investigated. The turnover rate ot VLDL-triglyceride 
was measured, in order to study the reason why these patients have very high 
concentrations of chylomicrons but only slightly elevated VLDL concentra­
tions, although both triglyceride-rich lipoproteins share the same removal 
mechanism. Family study was performed to establish the mode of inheritance 
of the various deficiencies in this family. 
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CHAPTER II 
MEASUREMENT OF THE TURNOVER RATE OF VERY LOW 
DENSITY LIPOPROTEINS 
21 
SUMMARY 
Several methods for measuring plasma VLDL turnover rate have been 
developed. In this chapter we describe these techniques and discuss their 
advantages and limitations. One method is based on the direct measurement 
of the splanchnic secretion rate but has the disadvantage of the technical 
complexity and hepatic venous catheterization. Another method is based on 
lipoprotein lipase-related plasma TG removal by a continuous heparin 
infusion. In all other methods use is made of radioisotopes for labeling the 
VLDL. The two most extensively used methods are the radioglycerol method 
and the VLDL-apoB method. In the first technique VLDL is labeled 
endogenously after a pulse injection of 2-3H-glycerol, whereas in the latter 
the decay of in vitro labeled l24-VLDL-apoB is followed in vivo. From the 
discussion it becomes clear that all these methods are based on certain 
assumptions which have not been completely validated. 
In our studies, described in the next chapters, we have used the radioglycerol 
method to determine the plasma TG turnover rate because of its simplicity. 
The procedure and validation of this method are therefore discussed in 
detail. Results of plasma TG turnover rate measurements in a large number 
of subjects are presented and the mechanism of hypertriglyceridemia is 
discussed. It appears that hypertriglyceridemia is a heterogeneous disorder 
caused predominantly by overproduction, but also impaired removal plays an 
important role in many subjects. 
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INTRODUCTION 
In the postabsorptive state plasma triglycerides (TG) are derived mainly 
from the liver and to a lesser extent from the intestine. The endogenous TG 
are transported in the blood as very low density lipoproteins (VLDL). 
Hypertriglyceridemia due to elevations of VLDL is one of the most common 
forms of hyperlipidemia.' VLDL metabolism is closely related with that of 
low density lipoproteins (LDL) and high density lipoproteins (HDL).2,3 
Measurement of the rate of production or removal of VLDL therefore has 
considerable interest not only with regard to the regulation of plasma VLDL 
concentration itself, but also to that of LDL and HDL. By kinetic studies 
more insight can be obtained into the physiology of normal lipoprotein 
transport and the pathophysiology of lipoprotein disorders. Furthermore, the 
mechanism of action of hypolipidemic therapy can be examined. 
Several methods have been developed to measure the turnover rate of 
plasma VLDL with or without use of different radioactive tracers. Many 
studies are based on labeling either the lipid core (TG) or the protein shell 
(apoprotein B) of VLDL. Each method implies certain assumptions which have 
not been completely validated. This may in part explain why investigations 
using different techniques of evaluating plasma TG kinetics in patients with 
hypertriglyceridemia have yielded conflicting results as to the cause of the 
increased plasma TG concentration: increased production or impaired remo-
val of plasma TG. Some of the methods for the quantification of VLDL 
turnover rate in man will be discussed. 
Direct measurement of the splanchnic secretion rate of VLDL-TG 
This method depends on the chemical measurement of artery-hepatic venous 
difference in VLDL-TG, multiplied by the simultaneously measured hepatic 
plasma flow.4·5 The precision of this method is low because of the small 
difference in VLDL-TG between arterial and hepatic venous blood. Simulta-
neous infusion of labeled fatty acid (FA) during sampling of arterial and 
hepatic venous blood and measurement of specific activity of VLDL-TGFA 
increases the precision. Contribution of precursors other than FA, however, 
is not taken into account. Furthermore, this method neglects entry of TG 
from intestinal lymph and the uptake of TG in the region drained by the 
portal vein. It is obvious that the hepatic venous catheterization and technical 
complexity of this method form important ethical and practical drawbacks, 
which make it not feasible for use on a large scale. 
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Determination of the production rate of VLDL-TG by means of intravenous 
administration of labeled precursors of VLDL-TG 
The production rate of VLDL-TG can be determined with use of labeled 
precursors (Z-'H-glycerol or l 4C-FFA) in two ways: (a) by measuring the rate 
of appearance of radioactivity in plasma VLDL-TG during a constant 
intravenous infusion of labeled FF A6"8 or (b) by analysis of the specific 
activity decay curves of plasma VLDL-TG after administration of labeled 
precursors.4*"11 The former method provides a minimal estimate of the rate 
of entry of VLDL-TG into the blood, because plasma FFA are not the sole 
precursors of VLDL-TG. The latter method lacks this disadvantage and will 
be described in more detail later (page 27). 
Measurement of VLDL-TG transport from the assessment of the maximal 
capacity of the removal system of plasma TG during a constant intravenous 
infusion of heparin 
By infusion of heparin, lipoprotein lipase (LPL) is released into the blood 
and the concentration of TG is reduced approximately 50% to a new steady-
state in 2-3 hours in subjects with normal TG and in 4-5 hours in subjects with 
elevated TG levels.1 2 1 3 Blood is drawn during this steady-state and the serum 
is incubated immediately in vitro at pH =7.4 and 370C to determine the rate 
of FFA release from the subjects own endogenous TG by the LPL present in 
the serum. This method assumes that the rate of lipolysis in vitro is equal to 
the rate of lipolysis in vivo and the rate of TG removal in vivo can thus be 
calculated. Measurement of the lipolytic rate may be difficult in subjects with 
low VLDL-TG concentration (no linear increase in FFA during the incuba­
tion in vitro due to a deficiency of substrate). By heparin infusion plasma 
FFA is increased and may produce enhanced hepatic uptake of FFA and 
secretion of VLDL-TG. Despite these limitations, indirect evidence for its 
validity is obtained by the close agreement in results between this method 
and other methods. 1 4 1 5 This method avoids the use of radioisotopes. 
Determination of the VLDL turnover rate after injection of autologous VLDL 
labeled in the apoprotein В moiety 
Apoprotein В is essential for the formation and structure of VLDL and 
remains with the particle throughout its catabolic cascade. Because it is 
quantitatively conserved during the conversion of VLDL via intermediate 
density lipoprotein (IDL) to LDL, this method gives the opportunity to 
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quantify the synthesis, interconversion and catabolism of VLDL, IDL and 
L D L . 2 1 6 1 7 This method is, however, very laborious. It includes sampling of 
plasma (50-100 ml) after an overnight fast for isolation of VLDL by ultracen-
trifugation for 16 hours at density 1.006 g/ml and purification by recentrifuga-
tion at this density. VLDL is then radioiodinated by the iodine monochloride 
method of McFarlane18 as modified for apolipoproteins by Langer et al.1 9 
After elimination of the free iodine and sterilization by ultrafiltration, the 
iodinated VLDL (10-40 цСі) is re-injected intravenously into the patient 
within 96 hours. Blood samples are obtained for the next 48 hours to 
determine the VLDL-apoprotein В specific radioactivity-time curve and for 
longer periods when radioactivity curves for IDL and LDL are also followed. 
The fractional catabolic rate (FCR) is determined from the descending slope 
of the curve. The absolute VLDL-apoB turnover rate (V) can be calculated 
from the formula: V = FCR χ VLDL-apoB pool size. VLDL pool size is 
obtained from VLDL-apoB concentration χ plasma volume. 
To minimize fluctuations in VLDL-apoB concentration, the patients receive 
a hypocaloric low fat diet before and during the study. During the study 
potassium iodide is administered to block the uptake of 1 2 5I by the thyroid 
gland. Figure 1 shows the results of a VLDL-apoB turnover rate determina­
tion in a normolipidemic subject performed in our department. 
The specific activity-time curves for 125I-VLDL-apoB and 125I-LDL-apoB 
appear to intersect at the maximum of the latter curve, which suggests a 
precursor-product relationship between VLDL and LDL. 2 0 The disappea­
rance rate of VLDL-apoB appears to be bi-exponential, suggesting the 
presence of at least two pools. These two pools may be explained by 
assuming several populations of VLDL particles with different secretion 
rates or with differences in their catabolic processes.21-22 In contrast, others 
found that the disappearance of VLDL-apoB was mono-exponential for at 
least 24 hours (4-5 half-lives) and argued that any subsequent tailing of the 
VLDL-apoB specific activity curve contributed little to the overall disappea­
rance rate. 2 , 2 3 
According to some authors, most of VLDL-apoB is normally converted into 
LDL-apoB,2 , 2 2 but according to others the percentage of conversion of 
VLDL-apoB to LDL-apoB is approximately 50%.1 7 In hypertriglyceridemia 
caused by oversecretion of VLDL-apoB only a minor fraction of VLDL-
apoB is converted into LDL-apoB.2•24 In type III hyperlipoproteinemia the 
conversion of VLDL-apoB via IDL- into LDL-apoB is delayed, whereas no 
precursor-product relationship exists any more between VLDL- and LDL-
apoB.2 3 
The TG/apoprotein ratio of VLDL can vary widely in patients with hypertri­
glyceridemia; so results with VLDL-apoB turnover studies need not to be 
identical to those of VLDL-TG kinetic studies. Simultaneous study of the 
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Figure 1. Specific activity-time curves for VLDL-apoB and LDL-apoB with Intersection 
at maximum of the LDL-apoB curve in a normal subject after a bolus injection of 
125l-VLDL-apoB. 
VLDL-TG- and VLDL-apoB turnover rate before and during high carbohy­
drate diets has demonstrated an increase in VLDL-TG production, whereas 
VLDL-apoB secretion remained constant 2 5 Apparently, VLDL can trans­
port more TG per particle Nevertheless, comparison of the two methods 
with a time interval of several days in subjects with a wide range in plasma 
TG showed a correlation of г = 0 67 1S In another study, the simultaneous 
measurement of the VLDL-TG- and VLDL-apoB turnover rate in 
normohpidemic subjects and in subjects with familial forms of hypertriglyce­
ridemia showed even very high correlations with correlation coefficients of 
r = 0 86 to r = 0 98 2b 
In common with other methods of turnover rate measurement, the validity of 
the VLDL-apoB turnover rate is not completely certain which may be related 
to the heterogeneity of VLDL and the labeling m vitro of VLDL, one has to 
assume that no changes are induced in biological and kinetic behaviour of the 
tracer In the studies reported so far, there were no changes in VLDL in 
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electrophoretic and density properties after labeling and after re-injection 
there were no signs of denaturation of the tracer.2·21 
Turner et al27 have measured directly the splanchnic secretion of apoprotein 
В containing lipoproteins, using apoprotein В as a marker, in subjects who 
underwent catheterization for coronary angiography. After labeling with 
radioiodine and re-injection of autologous lipoproteins, the artery-hepatic 
venous differences in apoprotein В mass, radioactivity and specific activity in 
different lipoprotein classes were measured. 
In conclusion, it may be clear that the determination of the VLDL turnover 
rate with labeled apoB as marker has certain advantages. Some preliminary 
VLDL-apoB turnover rate studies were performed (figure 1), but this 
method appeared to be too laborious and time-consuming to apply on a large 
scale. The determination of VLDL turnover rate with radioglycerol during a 
relatively short period is much easier to perform, but has certain limitations. 
Because of its simplicity we have employed this method to study the 
pathogenetic mechanism of several forms of hypertriglyceridemia (see also 
chapter III, IV and VII). The procedure and validation of this method will be 
described here in detail. 
MEASUREMENT OF THE VLDL-TG TURNOVER RATE AFTER A PULSE 
INJECTION OF RADIOGLYCEROL 
Procedure and validation 
The use of 2-3H-gIycerol for estimating VLDL-TG turnover rate was develo­
ped by Farquhar et al.9 In our laboratory we used the following protocol: 500 
μ Ο 2-3H-glycerol (The Radiochemical Centre, Amersham, England, specific 
activity 200-500 цСі/цтоІ) was dissolved in 5 ml sterile ethanol and diluted 
with 20 ml sterile saline. The mixture was again sterilized by ultrafiltration 
through a 0.22 μιτι disposable Millex filter unit (Millipore S.A. 67120, 
Molsheim, France) and stored at 40C until use. A dose of 50 цСі was 
administered intravenously as a pulse injection in a subject after an overnight 
fast. Blood samples were obtained from the opposite arm through a needle 
kept patent by a saline drip, at 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6 and 7 hours after 
administration of the tracer for the determination of radioactivity and 
concentration of VLDL-TG and/or total serum TG. The subject kept fasting 
during the study. 
VLDL were isolated from 3 ml of serum as described previously.28 After 
ultracentrifugation the VLDL were concentrated in the top layer and aspira­
ted in approximately 2.5 ml. Two ml of this solution were used for the 
determination of TG-radioactivity and in the remainder TG concentration 
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Figure 2. Specific actlvlty-tlme curves for total plasma TG and VLDL-TG after labeling In 
vivo with 2-3H-glycerol In a normal subject. 
was determined. In most experiments the fractionation of VLDL was omit­
ted (see below) and serum samples were stored frozen until analyzed. TG 
were extracted according to Royer and Ko1 9 using η-heptane instead of 
nonane: 2 ml of serum or of VLDL fraction were extracted with 22 ml 
extraction solvent (containing η-heptane: isopropanol 2 : 3.5 v/v) and 4 ml 
0.08 N H2SO4 in extraction tubes (20 χ 2 cm). The tubes were vigorously 
shaken by hand twice for one minute and after waiting for 5 minutes 6 ml of 
the upper layer were pipetted into a counting vial (total volume of the upper 
layer was 7.35 ml when serum and 7.6 ml when VLDL was extracted). The 
extraction solvent was evaporated by means of an air stream and the residue 
was dissolved in 10 ml PPO (diphenyloxazol)-toluene liquid scintillation 
fluid. The radioactivity was measured in a Nuclear Chicago Mark II Liquid 
Scintillation Analyzer twice during 10 minutes. TG was determined in a 
separate sample as described by Demacker et al.1 0 With the extraction 
method more than 97% of the TG present in the serum could be extracted. 
The extract contained negligible amounts of phospholipids, glycerol and 
glucose (unpublished data). 
Specific activity of VLDL-TG or total serum TG is plotted against time on a 
semi-logarithmic scale. Shortly after the injection of 2-3H-glycerol there is an 
initial build-up in specific activity, followed by a mono-exponential decay for 
several hours thereafter. The slope of the fall in specific activity is determi-
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Figure 3. Specific actlvlty-tlme curves for total plasma TG and VLDL-TG after labeling In 
/Ivo with 2-aH-glycerol In a hypertrlglycerldemlc subject. 
tied with the method of the least squares. From this slope the FCR and half-
life can be obtained. The product of FCR, mean (VLDL)-TG concentration 
during the experiment and plasma volume gives the absolute turnover rate. 
Plasma volume is calculated from hematocrit and a nomogram for deriving 
blood volume from height, weight and sex with a correction for overweight.31 
As this study is done during a period when plasma VLDL-TG concentration 
is in a steady-state, the removal rate, turnover rate and production rate are 
equal. Figure 2 depicts an example of a study in a normolipidemic subject. 
Піе procedure can be simplified by omitting the lipoprotein fractionation. 
The slope of the radioactivity decay curve for total plasma TG and for 
VLDL-TG are almost identical, particularly when VLDL-TG concentration 
s elevated (figure 3). The turnover rates of total plasma TG and VLDL-TG 
η 17 studies (10 normolipidemic and 7 type IV subjects) correlated closely 
'figure 4). In agreement with previous studies it seems therefore reasonable 
:o omit lipoprotein fractionation.10,32 
The measurement of VLDL-TG turnover with radioglycerol in a patient with 
severe hypertriglyceridemia may be impossible. Figure 5 depicts the results in 
Ì patient with a plasma TG concentration of 38.2 mmol/1. The specific 
jctivity curve of the labeled TG does not decline during the study period, so 
:hat no FCR can be obtained. This must be explained by the huge size of the 
plasma TG pool. 
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Figure 4. Relation between turnover rates (V) of total plasma TG and VLDL-TG In 17 
measurements. The equation of the regression line Is given. 
During the study of VLDL-TG turnover rate the presence of a steady-state in 
plasma TG is obligatory Only then TG removal is equal to TG production 
rate For that reason measurements were accepted only when the variation in 
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Figure 5. Specific activity-time curve of labeled plasma TG In a patient with severe 
hypertriglyceridemia. There is no decline in specific activity. 
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plasma TG during the study period was less than 10%. Of our experiments 
8% had to be rejected because of an insufficient steady-state. 
In the literature no data are provided about the reproducibility of this 
method to measure VLDL-TG turnover rate. We examined this in 8 patients 
by measuring plasma TG turnover rate on two different occasions (with an 
interval of at least several days to months). These studies were performed on 
an out-patient basis in normotriglyceridemic subjects who used a free diet. 
The results are presented in figure 6. There is a close similarity in VLDL-TG 
turnover rates in 3 subjects with similar plasma TG concentrations during 
both measurements. In the remaining subjects with dissimilar plasma TG 
concentrations on both occasions, VLDL-TG turnover rates are also dissimi-
lar. However, the changes in VLDL-TG turnover rate and plasma TG must 
be interpreted in relation with the saturation curve, describing the normal 
relationship between plasma TG concentration and turnover rate as a process 
with Michaelis-Menten kinetics. The change in plasma TG and turnover rate 
of both measurements parallels this curve in all cases. Thus, the fact that 
dissimilar turnover rates are found at dissimilar TG levels in the same 
subjects, does not argue against a good reproducibility, because these chan-
ges are in the same direction as could be expected from the saturation curve. 
(This will be discussed in more detail later (page 33). From these studies it 
can be concluded that when plasma TG turnover rate is measured under 
identical plasma TG concentrations, the reproducibility of the method is 
fairly good (coefficient of variation < 10%). 
V T G ( / j m o l . k g - 1 . h - 1 ) 
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Figure 6. Repeated plasma TG turnover rate (VT0) measurements In eight normal 
subjects. The saturation curve describing the relationship between plasma TG turnover 
rate and concentration In a normal control group (fig. 7) Is shown as a broken line. 
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The method described to measure plasma TG turnover rate implies the 
following assumptions: 
a. The radioactivity disappearance rate represents only the turnover rate of 
labeled TG when it is assumed that the turnover rate of the precursor 
(glycerol) in the liver is appreciably greater than that of the product in the 
plasma (labeled TG in VLDL). This has been confirmed by re-infusion 
experiments, in which the FCR of endogenously labeled VLDL was identical 
to that of pre-labeled and re-injected VLDL. 9 1 1 
b. It is assumed that the plasma VLDL is metabolically homogeneous. 
Plasma VLDL particles differ, however, in size and density. It has been 
shown that larger and less dense particles are cleared more rapidly than 
smaller and denser particles.33 Measurement of the turnover rate of the 
whole VLDL fraction would then reflect the overall rate by which plasma TG 
is removed from the plasma. In fact, the slope for the whole VLDL fraction 
actually measured, correlated closely with the calculated slope from the 
different specific activity curves for each VLDL subfraction (г = 0.92).33 
c. It is assumed that the disappearance rate of TG from the plasma is mono-
exponential and that the exponential rate constant represents a valid measure 
of the FCR. Therefore, only curves with a mono-exponential decline are 
accepted for analysis. However, Zech et al34 have recently shown by exten­
ding the observation period to 48 hours that the decay is not monoexponen-
tial but biphasic due to a slow component or "tail" arising 12-18 hours after 
injection of the tracer, caused predominantly by a slowly turning-over 
precursor compartment, requiring multicompartmental analysis. Earlier it 
was believed that the tail was caused by recycling (re-use of the label 
released during lipolysis of VLDL returning to the liver).9 Recycling, howe­
ver, does not contribute to the tail since only a minor fraction of the free 
glycerol (<10%) is incorporated in VLDL-TG and the turnover of glycerol 
is very fast.33 Computer-simulated curves showed also that VLDL-TG radio­
activity curves were insensitive to recycling.34 Normally, the tail is not caused 
by a slowly turning-over VLDL-TG component in the plasma. Only in 
patients with severe type III hyperlipoproteinemia (VLDL-cholesterol/ 
VLDL-TG ratio above 1.50) the slowly turning-over plasma VLDL remnants 
contribute largely to this tail.3 4 , 3 5 Type III patients were not included in our 
studies described here. Therefore, by ignoring the slow component during 
measurements of shorter duration the results may not be completely correct 
in absolute terms. However, there is a statistically significant correlation 
between the relatively short measurements with mono-exponential analysis 
and prolonged measurements with multicompartmental analysis (r = 0.55, 
ρ < 0.05, for normal weight subjects36). Despite its limitations, the measu­
rement of VLDL-TG turnover during a relatively short period is still valua­
ble, as appears from the fact that a close correlation has been found between 
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Table 1. Results of plasma TG turnover rate measurement In normotrlglycerldemlc 
subjects with the radloglycerol method (mono-exponential analysis) by different 
authors. Results are expressed as mean ± SD. 
Authors 
Nikkilä and Kekki10 
Olefski et al37 
Angelin et al38 
Present study 
Number of 
subjects 
(Male, Female) 
34 (18, 16) 
21 ( 8, 13) 
19* ( 9, 10) 
17 (11, 6) 
Plasma TG 
coacentration 
(mmol/l) 
0.73 ± 0.25 
1.10 ± 0.38 
1.28 ± 0.32 
1.09 ± 0.33 
Plasma TG 
turnover rate 
(цтоі · kg ' · IT') 
8.7 ± 2.8 
10.5 ± 2.5 
10.5 ± 3.1 
9.9 ± 3.0 
'patients with type Ila hyperlipoproteinemia 
the turnover rates measured by this method and the simultaneously measu­
red VLDL-apoB turnover rates in normolipidemic subjects (r = 0.98) and 
in subjects with familial forms of hypertriglyceridemia (r = 0.94 and г = 
0.86, respectively).26 
Results in normal subjects and subjects with hypertriglyceridemia 
The results for plasma TG turnover rate as found in 17 normotriglyceridemic 
subjects are summarized in table 1; compared with the data of other authors 
using the same method, these results are in close agreement (table 1). When 
the results obtained in 7 diabetic subjects with normal plasma TG levels are 
included in those of our non-diabetic control group the mean plasma TG 
turnover rate is 10.1 цто1.к£"1.Ь"1 (range 5.0-13.3), the mean plasma TG 
concentration 1.14 mmol/l (range 0.58-1.92) and the mean FCR 0.25 h"1 
(range 0.14-0.35). Plasma TG turnover rate of these subjects was positively 
correlated with plasma TG concentration (figure 7). The regression line 
calculated from our data resembles closely the regression line calculated from 
the data of Nikkilä and Kekki10 (figure 7). Reaven et al39 have stated that the 
relationship between plasma TG concentration and turnover rate in a group 
of normal and hypertriglyceridemic subjects could be described best by a 
hyperbolic curve. They were the first to characterize plasma TG metabolism 
in terms of conventional enzyme kinetics. In analogy with the Michaelis-
Menten formulation described for saturable enzyme systems, maximal remo-
val capacity (Vmax) and the Km value were calculated by linear transformation 
of their data (plotting S/V versus S). Reaven et al39 concluded that plasma 
TG concentration is determined by the input rate up to a relatively fixed 
point of saturation of plasma TG removal and that it increases rapidly with a 
further increase of TG production. Nikkilä and Kekki extended and confir-
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Figure 7. Relationship between plasma TG turnover rate (VTQ) and concentration In 24 
normollpldemlc subjects (Including seven diabetic subjects). The regression line shows 
a good agreement with that calculated from the data of Nlkkllä and KeKki* (broken line). 
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Figure 8. Schematic diagram of possible mechanisms of hypertriglyceridemia based 
on the relation between plasma TG concentration and turnover rate. The saturation curve 
derived from a normal population is also shown. 
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med the observations by Reaven et al by studying a large group of normal 
subjects. They found a polymorphism of TG transport in their population 
with different V
max
 and identical K,,, values in subgroups.10 According to the 
latter authors plasma TG concentration is determined by: turnover rate (V), 
maximal velocity of removal (V
ma
,) and K
m
 of the removal enzyme(s). In 
normal women lower K
m
 values were found than in men,10 suggesting that 
women have a more efficient removal system. Thus, women will have lower 
plasma TG concentration for any given TG turnover rate. 
The mechanism in different hypertriglyceridemic states can be demonstrated 
by plotting plasma TG turnover rate versus TG concentration; the individual 
results must then be interpreted in relation with the saturation curve derived 
from the normal population and extrapolated to the hypertriglyceridemic 
area. Figure 8 depicts a schematic diagram of possible mechanisms of 
hypertriglyceridemia. 
Figure 9 shows our results in a group of normotriglyceridemic subjects in 
comparison with those in subjects with primary hypertriglyceridemia or 
V T e ( / u m o l . kg- 1 .h- 1 ). 
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Figure 9. Plasma TG turnover rate (VTQ) In a group of subjects with normal plasma TG 
levels and In a group with hypertriglyceridemia (type IV). Non-dlabetlc and (non-lnsulln-
dependent) diabetic subjects are Indicated. 
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hypertriglyceridemia secondary to (non-insulin-dependent) diabetes. The 
mean TG turnover rate is increased, but there is a considerable overlap 
between the two groups. Thus, in type IV subjects production rates can be 
normal or increased. In the case that TG production rate is normal, a 
defective removal of plasma TG must exist. The individual turnover rate 
studies are graphically shown in figure 10 in relation to the saturation curve 
calculated from the data of Nikkilä and Kekki.10 This figure illustrates the 
mechanism of hypertriglyceridemia in the individual subjects better than 
figure 9. 
In the whole group of subjects there is a positive correlation between plasma 
TG concentration and turnover rate (r = 0.65, ρ < 0.001). So, overpro­
duction of plasma TG seems to be a major cause for the development of 
hypertriglyceridemia. However, there is a great number of subjects with 
decreased removal efficiency (figure 10). Concerning its pathogenesis, type 
IV hyperlipoproteinemia appears therefore to be a heterogeneous disorder 
both in diabetic and in non-diabetic subjects. The results we have obtained in 
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Figure 10. Relationship between plasma TG turnover rate (VTa) and concentration In 
104 subjects (non-diabetics and diabetics). The curved line represents the saturation 
curve, calculated from the data of Nikkilä and Kekki,8 extrapolated to the hypertrigly-
cerldemic area. 
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our hypertriglyceridemic subjects agree well with previous reports.37,38 The 
heterogeneity in pathogenetic mechanism may explain in part the conflicting 
results as to the cause of hypertriglyceridemia in earlier reports.4:>·37 Determi-
nations of VLDL-apoB turnover rate have confirmed the overproduction of 
VLDL in the majority of the patients with type IV hyperlipoprotein-
17 40 41 
ernia.1 • W · ' 
37 
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SUMMARY 
Fourty-five patients with primary hypertriglyceridemia (type IV phenotype) 
were defined genetically by family investigation Twenty-two subjects were 
diagnosed as having familial combined hyperhpidemia (FCH), 14 subjects as 
having familial hypertriglyceridemia (FHT), whereas 9 subjects could not be 
classified 
Several metabolic variables of plasma triglyceride metabolism were studied 
in search for possible differences between these groups Plasma high density 
lipoprotein (HDL)-cholesterol was equally decreased m the genetically dis­
tinct groups The concentration of plasma very low density (VLDL)-triglyce-
ndes was inversely correlated with HDL-cholesterol both in normal controls 
and in the two genetic groups The composition of the VLDL fraction 
expressed as ratio of VLDL-cholesterol/VLDL-tnglycendes was not diffe­
rent in the groups with FCH and FHT, these ratios were slightly but 
insignificantly lower than in normal controls 
The mean concentration of low density lipoprotein (LDL)-cholesterol and 
the mean ratio of LDL-/HDL-cholesterol were higher in subjects with FCH 
than in those with FHT, but these differences just failed to be significant The 
ratio LDL-/HDL-cholesterol was significantly higher in subjects with FCH 
than in normals, whereas this ratio was not increased in subjects with FHT 
Posthepann lipoprotein lipase and hepatic lipase activity were not signifi­
cantly decreased in either group Determination of the apohpoprotein С 
composition of the VLDL fraction, which may modulate lipoprotein lipase 
activity, did not reveal any differences between the genetic groups In 
particular, the ratio of apoC-II/C-III and the relative amount of the subspe­
cies apoC-III] and ароС-ІІІ2 were not significantly different from those of 
normal subjects Only in subjects with FHT, there was a slight but significant 
increase in the relative amount of the non sialylated form of apohpoprotein 
C-III, C-Ilio, compared to normals 
Both in FCH and in FHT the turnover rate of plasma triglyceride was 
increased in the majority of the patients, but in some patients the turnover 
rate was in the normal range In the latter subjects hypertriglyceridemia must 
be due to impaired TG removal There was no significant difference in the 
mean turnover rate of plasma triglyceride between FCH and FHT 
It is concluded that in individual patients with type IV phenotype on different 
genetic basis no specific metabolic marker is present to distinguish subjects 
with FCH from those with FHT Furthermore, the risk of cardiovascular 
disease in FCH may be explained by the increased LDL-/HDL-cholesterol 
ratio 
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INTRODUCTION 
Hypertriglyceridemia is one of the most common forms of hyperlipidemia 
and frequently associated with premature atherosclerosis.1 There is still 
disagreement as to the magnitude of the risk of elevated plasma triglycerides 
(TG) of early development of atherosclerosis. Prospective population studies 
with application of multivariate analysis including HDL-cholesterol, which is 
inversely correlated with coronary heart disease,2 have shown that plasma 
TG concentration is not an independent risk factor.1,4 In these studies its risk 
is derived from secondary associations with atherosclerosis such as the 
negative correlation of plasma TG with HDL-cholesterol. It has been esta­
blished, however, that hypertriglyceridemia comprises a heterogeneous 
group of primary and secondary disorders. It seems important to recognize 
subgroups which do have an increased risk and may benefit by early 
treatment. 
Two distinct monogenetic forms of hypertriglyceridemia have been recogni­
zed: familial hypertriglyceridemia (FHT) with affected family members who 
have only elevated plasma VLDL concentration (type IV phenotype), and 
familial combined hyperlipidemia (FCH) with affected family members who 
may have either a rise of plasma VLDL (type IV phenotype), of plasma 
LDL (type IIa phenotype) or of both lipoproteins (type lib phenotype).5 The 
frequency of myocardial infarction has been reported to be increased among 
families with FCH, subjects with elevated VLDL levels having the same risk 
as subjects with elevated LDL levels, whereas the frequency of myocardial 
infarction in subjects with FHT was similar to normolipidemic controls.6 
Thus, subjects with the type IV phenotype from a family with FCH seem to 
carry a greater risk than subjects with the type IV phenotype from a family 
with FHT. Since no specific biochemical marker has yet been detected for 
either FHT or FCH, investigation of rather large families is needed to 
establish the diagnosis in individual patients. 
The pathogenesis of FHT and FCH does not need to be identical. Kinetic 
studies have been performed so far only in a limited number of subjects, 
including subjects with different lipoprotein phenotypes.7-9 We have compa­
red various metabolic characteristics in a group of genetically well defined 
subjects with the type IV phenotype in an attempt to distinguish FHT from 
FCH in subjects with primary hypertriglyceridemia. These metabolic charac­
teristics include the concentrations of plasma VLDL-TG and VLDL-, LDL-
and HDL-cholesterol, the activities of postheparin plasma LPL and hepatic 
lipase, the composition of the apoproteins С of the VLDL fraction and the 
turnover rate of plasma TG. LPL is a key-enzyme in the catabolism of TG-
rich lipoproteins;10 apoC consists of several peptides of which apoC-II is 
known as the specific activator of LPL,1 1 whereas apoC-III inhibits the 
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activation of LPL by apoC-II in vitro. A regulatory role has been ascribed 
to the ratio of VLDL apoC-II/C-III in the removal of plasma TG. 1 3 1 4 Plasma 
TG turnover rate measured during a steady-state gives an estimate of the rate 
of secretion (and removal) of plasma TG. 
MATERIALS AND METHODS 
Subjects 
The 45 index patients (40 males, 5 females) were selected from the outpa­
tients' department for internal medicine on the basis of persistent hypertri­
glyceridemia and preferably the existence of a large family. All subjects had 
the type IV phenotype, defined as fasting plasma TG >2.00 mmol/1 without 
chylomicronemia and plasma LDL-cholesterol <5.20 mmol/1).15 There was 
no clinical or biochemical evidence for renal, thyroid or liver disease nor 
excessive alcohol intake. Patients with diabetes mellitus (fasting plasma 
glucose >8.0 mmol/1) were excluded, but seven of the 45 subjects had an 
impaired glucose tolerance test (2 hours value after 100 g of glucose >8.0 
mmol/1). Drugs known to affect lipid metabolism were withheld for at least 2 
months prior to this investigation, except for β blocking agents in 13 patients 
who were using these drugs because of hypertension and angina pectoris. 
Although it is known that some of these drugs produce small changes in 
serum lipids, this medication was not discontinued for ethical reasons. 
During the investigation the patients were using an isocaloric diet containing 
approximately 45% of calories as carbohydrates, 40% as fat and 15% as 
protein. 
Study Protocol 
For genetic classification fasting blood was sampled from 218 first-degree 
relatives (parents and siblings). Children were not included because full 
expression of FCH or FHT is not evident until the end of the second decade.5 
Most relatives came to our department for blood sampling, a few fasting 
blood samples were mailed to our laboratory. A complete lipoprotein 
analysis was performed in the majority of the normolipidemic relatives 
(fasting plasma TG <2.0 mmol/1, plasma cholesterol <7.3 mmol/1, LDL-
cholesterol <5.20 mmol/1), of relatives with elevated TG concentration and 
in all relatives with elevated cholesterol level. Patients were classified accor­
ding to the criteria of Goldstein et al5 as having FHT when at least one, 
preferably two or more relatives had only hypertriglyceridemia. They were 
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classified as having FCH when besides hypertriglyceridemia one or more 
relatives had hypercholesterolemia (LDL-cholesterol >5.20 mmol/l). Index 
patients were designated as unclassified hypertriglyceridemia (UNC) when 
first-degree relatives showed no evidence of hyperlipidemia or when too few 
lipoprotein analyses were available to identify the genetic basis. 
The following determinations were performed in the index patients: 
a. cholesterol and TG in whole plasma and in the VLDL fraction and 
cholesterol in the LDL- and HDL fraction. 
b. the apoprotein С composition of the VLDL fraction. 
с LPL and hepatic lipase in postheparin plasma (once or twice). 
d. plasma TG turnover rate with 2-3H-glycerol. 
Methods 
All blood samples were obtained after an overnight fast. Lipoproteins were 
fractionated by preparative ultracentrifugation as described previously.16 
HDL was isolated after precipitation of LDL in the d > 1.006 g/ml fraction 
with heparin/Mn2+. Cholesterol was determined with an enzymatic 
method17 and TG with a semi-automated colorimetrie method.18 The Tris-
urea soluble apoproteins of the VLDL-fraction were semi-quantitatively 
measured with isoelectric focusing according to Weidman et al19 slightly 
modified as described elsewhere20 (chapter VII). LPL and hepatic lipase 
were measured with an immunochemical technique 15 minutes after injection 
of 50 U of heparin per kg body weight as previously described20 (chapter VII). 
The turnover rate of plasma TG was assessed according to Farquhar et al21 
and Nikkilä and Kekki22 after an intravenous injection of 50 цСі 2-3H-
glycerol as described earlier (chapter II). Plasma TG radioactivity and 
concentration were determined in nine blood samples until seven hours after 
administration. The fractional catabolic rate was obtained from the descen­
ding slope of the plasma TG radioactivity curve. From the product of the 
fractional catabolic rate, the mean plasma TG concentration during the study 
period and the plasma volume the plasma TG turnover rate was calculated. 
Plasma volume was calculated from hematocrit and a nomogram for deriving 
blood volume from weight and sex with a correction for overweight23 
(chapter II). 
All investigated subjects gave informed consent and the study protocol was 
approved by the University Hospital's Ethical Committee. 
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Statistics 
For statistical analysis Student's t-test for unpaired data and the correlation 
coefficient according to Pearson were used. P-values less than 5% were 
considered to be significant. All results are presented as mean ±SD. 
RESULTS 
Genetic classification 
Thirty-six of the 45 index patients could be classified genetically. Twenty-two 
patients were diagnosed as FCH and fourteen as FHT. Figure 1 depicts 
pedigrees of two families with the distinct genetic forms of hyperlipidemia. 
Of the twenty-two index patients with FCH 120 first-degree relatives (86% of 
the living parents and siblings) were investigated: 42 relatives (35%) were 
normolipidemic; the type IIa phenotype was found in twelve relatives (10%), 
Familial combined hyperlipidemia 
1 i 1 U 1 i i 
1 2 3 U S 6 7 β 
Familial hypertriglyceridemia 
¿ ¿ ¿ ¿ ¿ ¿ ¿ 
1 2л 3 i 5 6 7 
j plasmaT3 LDL-chol 
0
 V (mmol/l) (mmol/l) 
Β θ normal <2.0 < 5.2 
Η Q type IV phenotype > 2 . 0 < 5.2 
Η β type IIa phenotype < 2 . 0 > 5.2 
• # type I I b phenotype > 2 . 0 > 5.2 
• О not analyzed 
/ denotes proband 
Figure 1. Pedigrees of a family with familial combined hyperlipidemia and with familial 
hypertriglyceridemia. 
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Table 1. Clinical data and fasting plasma lipid concentrations of distinct genetic groups 
of patients with hypertriglyceridemia. Data are given as mean ± SD. 
Genetic 
Group 
FCH 
FHT 
UNC 
Number of 
subjects (m,f) 
22 (19, 3) 
14 (12, 2) 
9 ( 9, 0) 
Age 
(yrs) 
49 ± 9 
44 ± 9 
48 ± 9 
Rei Body 
weight (%) 
118 ± 11 
113 ± 12 
114 ± 11 
Cholesterol 
(mmol/1) 
6.73 ± 1.18 
6.00 ± 1.17 
6.59 ± 0.56 
Triglycerides 
(mmol'l) 
4.71 ± 1.96 
4.31 ± 1.34 
4.73 ± 2.02 
FCH: lamlllal combined hyperllpldemla; FHT: familial hypertriglyceridemia; 
UNC: unclaasHied hypertriglyceridemia 
the lib phenotype in thirty-three relatives (28%), the type IV phenotype in 
thirty-two relatives (27%) and the type III phenotype in one relative. 
Of the fourteen index patients with FHT 86 first-degree relatives (90% of the 
living parents and siblings) were studied: 48 relatives (56%) were 
normolipidemic and thirty-eight relatives (44%) had the type IV phenotype. 
Of two index patients with UNC there was no evidence for hyperlipoprotein-
emia in three and four relatives, respectively. Of the remaining patients two 
had one relative with the type IV phenotype, but there were not enough 
relatives available for exact classification. 
Some clinical data and the fasting lipid concentrations of the index patients in 
the various groups are summarized in table 1. There were no significant 
differences in age, sex, RBW, plasma cholesterol and TG concentrations 
between the genetic groups. 
Plasma lipoproteins and VLDL composition 
The VLDL-TG and the VLDL-, LDL- and HDL-cholesterol concentrations 
are summarized in table 2. The VLDL-TG and VLDL-cholesterol values 
were significantly higher by selection in the hypertriglyceridemic groups than 
in normal male controls. LDL-cholesterol concentrations in each group of 
patients did not differ significantly from normal male controls. The mean 
LDL-cholesterol concentration was slightly higher in subjects with FCH than 
in subjects with FHT (3.97±0.84 vs 3.36±0.99 mmol/1) but the difference just 
failed to reach the significance level (p=0.056). HDL-cholesterol was signifi-
cantly lower in each of the three hypertriglyceridemic groups compared with 
normal male controls. Among the groups of patients there were no signifi-
cant differences in the concentration of HDL-cholesterol. The mean LDL-/ 
HDL-cholesterol ratio was significantly higher in subjects with FCH and 
UNC compared with normal controls, but not in subjects with FHT (table 2). 
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Table 2. Plasma VLDL-cholesterol and -TG concentration and LDL- and HDL-cholesterol 
concentration in the genetic groups with hypertriglyceridemia In comparison with a 
group of normolipidemlc subjects. The VLDL lipid composition (cholesterol/TG ratio) 
and LDL-/HDL-cholesterol are also shown. Results are presented as mean ± SD. 
Genene 
Group 
FCH (ii=22) 
FHT(n = 14) 
UNC (n=9) 
NomiaL males (n= •21) 
Normal females (n=I6) 
VLDL-chnl 
(mmoLl) 
1 97 ± 0 79-
1 76 ± 0 65* 
2 08 ± 0 92* 
0 43 ± 0 20 
0 23 ± 0 14 
VLDL TG 
(mmol·!) 
3 70 ± 1 62" 
3 35 ± 1 20' 
3 91 ± 0 27* 
0 72 ± 0 27 
0 39 ± 0 16 
LDL-chol 
(mmolll 
3 97 ± 0 84 
3 36 ± 0 99 
3 73 ± 0 75 
3 72 + Ü 87 
3 24 ± 0 97 
HDL -chol 
(mmol/l) 
0 89 ± ΟΣΙ­
Ο 92 ± 0 24' 
0 80 ± 0 15· 
1 22 ± 0 22 
1 69 + 0 39 
VLDL-chol' 
VLDL TG 
ratio 
0 56 ± 0 12 
0 54 ± 0 14 
0 55 ± 0 10 
0 62 ± 0 14 
0 62 ± 0 17 
LDL-chol' 
HDL-chol 
ratio 
4 70 ± 1 42 ' 
3 76 ± 1 30 
4 73 ± 1 03· 
3 17 ± 1 07 
2 06 ± 0 98 
FCH: familial combined hyperllpldemla; FHT: familial hypertriglyceridemia; 
UNC: unclassified hypertriglyceridemia 
' ρ <0.001 versus normal males 
The LDL-/HDL-cho]esterol ratio was higher in subjects with FCH than in 
subjects with FHT, but this difference again just failed to reach the signifi­
cance level (p=0.054). HDL-cholesterol was inversely correlated with 
plasma TG concentration both in the two genetic groups and in the normal 
controls (FCH: r = - 0 . 5 5 , p<0.01, FHT: г=0.65, p<0.05, normal controls 
(males plus females) r = — 0.47, p<0.01). The inverse correlation between 
HDL-cholesterol and VLDL-TG was even stronger (FCH: r = - 0 . 5 9 , 
p<0.01, FHT: r = - 0 . 6 4 , p<0.05, normal controls: r = - 0 . 5 6 , p<0.001). 
The ratios of VLDL-cholesterol/VLDL-TG, as an indirect estimate of the 
TG content of the VLDL, were equal in the different groups with hypertri­
glyceridemia; these ratios were slightly lower compared with the normal 
Table 3. Relative concentrations of VLDL apoprotein C-lll0, C-lll, and C-lll2 and apopro­
tein C-ll/C-lll ratio in the genetic groups of patients with hypertriglyceridemia In compari­
son with a group of normolipidemlc subjects. Results are presented as mean ± SD. 
Genetic apoC-III,, apoC-III, apoC-III, apoC-II/C-III 
Group ratio 
(Cr of total VLDb apoC-III) 
FCH (n=22) 18.8 ± 6.3 44.1 ± 4.9 37.1 ± 3.4 0.19 ± 0.05 
FHT (n=14) 20.2 ± 4.3* 42.5 ± 3.8 36.9 ± 4.6 0.20 ± 0.05 
UNC (n=9) 15.6 ± 4.9 48.6 ± 4.7 34.8 ± 3.2 0.18 ± 0.06 
Normal controls (n=37) 16.1 ± 5.3 45.5 ± 5.9 38.4 ± 4.6 0.18 ± 0.07 
FCH: familial combined hyperlipidemia; FHT: familial hypertriglyceridemia; 
UNC: unclassified hypertriglyceridemia 
* ρ < 0.05 versus normal controls 
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group, but these differences were not significant (table 2). 
The relative concentrations of the variously sialylated VLDL apoC-III 
peptides (apoC-III0, apoC-IIIj and apoC-IIb) and the ratio apoC-II/C-III 
were similar among the different groups with hypertriglyceridemia (table 3). 
In subjects with FHT there was a small but significant increase in the relative 
concentration of the apoC-III peptide without sialic acid residue (apoC-IIl
n
) 
compared with the normal controls. No significant correlations were found 
between the ratio apoC-II/C-III and plasma TG or HDL-cholesterol concen­
tration in the various groups. 
Postheparin lipolytic activities 
The results concerning the postheparin lipolytic activities are summarized in 
table 4. LPL and hepatic lipase activity were not significantly decreased in 
the different groups. In normal control subjects and in patients with FCH 
postheparin LPL activity was not correlated with plasma TG concentration 
(r=-0.23, ns and r=-0.23, ns, respectively). In the group with FHT, 
Table 4. Lipoprotein lipase (LPL) and hepatic lipase activities In postheparin serum (50 
U/kg) In the genetic groups with hypertriglyceridemia In comparison with normollpide-
mlc subjects. Results are presented as mean ± SD and ranges. 
Genetic group LPL hepatic lipase 
μιτιοΙ FFA · ml 
FCH (n=22) 6.9 ± 3.4 26.9 ± 12.1 
(2.7 - 14.8) ( 9.8 - 58.8) 
FHT(n=14) 7.2 ± 3.5 25.9 ± 10.6 
(3.2 - 15.3) (10.9 - 48.7) 
UNC (n=9) 7.5 ± 2.5 31.8 ± 12.0 
(4.4 - 12.8) (11.7 - 51.7) 
Normal males (n=14) 8.0 ± 2.5 25.9 ± 9.1 
(4.6 - 12.9) ( 9.8 - 41.8) 
Normal females (n=15) 8.9 ± 2.2 16.2 ± 6.2 
(5.8 - 14.1) ( 6.5 - 27.4) 
FCH: familial combined hyperllplòemla; FHT: familial hypertriglyceridemia; UNC: unclassified hyper-
triglyceridemia 
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however, LPL correlated inversely with plasma TG concentration ( r = - 0 . 6 1 , 
p<0.05). 
LPL was positively correlated with HDL-cholesterol concentration both in 
normal subjects (r=0.40, p<0.05) and in subjects with FCH (r=0.52, 
p<0.05), but not in subjects with FHT (r=0.11, ns). There were no correla­
tions between LPL activity and the ratio of apoC-11/C-III in the various 
groups. 
Plasma TG kinetics 
The results of the measurements of the plasma TG turnover rate are 
presented in table 5 and in figure 2. The mean plasma TG turnover rate in 
control subjects (11 males, six females, RBW 118±19%) was 9.9 μπιοί 
TG.kg-'.hf1 (range 5.7-15.0 μιποί TG.kg-'.h"1). 
The mean plasma TG turnover rate was increased in FCH: 16.7 цтоі 
TG.kg"1.h"1 (range 6.8-30.7 μιηοΐ TCkg" 1 . ! !" 1). Two measurements had to be 
rejected because of an insufficient steady-state in plasma TG during the study 
period. 
Mean plasma TG turnover rate was also increased in FHT: 19.2 μπιοί 
TG.kg"1.h"1 (range 10.3-25.9 μπιοί TG.kg"1.h"1). One measurement was 
rejected because of an insufficient steady-state in plasma TG. In subjects 
with FHT the mean plasma TG turnover rate was slightly higher than that in 
subjects with FCH, but this difference was not statistically significant. In 
subjects with UNC plasma TG turnover rate ranged from 6.5 to 28.8 μπιοί 
TG.kg' .h" 1 . In all three groups of patients there was an overlap in results of 
plasma TG turnover rate with those in the normolipidemic control group 
(figure 2). 
Table 5. Plasma TG turnover rate, fractional catabollc rate (FCR) and plasma TG 
concentration In the groups of patients with primary hypertriglyceridemia. Results are 
presented as mean ± SD. 
Genetic 
group 
FCH (n=20) 
FHT(n = 13) 
UNC (n=9) 
Normal controls (n = = 17) 
I'G turnover 
rate (μπιοΐ/kg h) 
16.7 ± 5.7** 
19.2 ± 5.1** 
18.2 ± 5.Γ* 
9.9 ± 3.1 
FCR 
(h •) 
0.14 ± 0.05** 
0.15 ± 0.05** 
0.14 ± 0.05** 
0.26 ± 0.06 
Plasma TG* 
(mmol/l) 
3.81 ± 1.57** 
3.57 ± 1.18** 
3.82 ± 1.61** 
1.09 ± 0.33 
FCH: familial combined hyperllpidemia; FHT: familial hypertriglyceridemia; UNC: unclassified hyper­
triglyceridemia 
* mean of 9 samples during the study period 
" ρ < 0.001 versus normal controls 
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Figure 2. Results of Individual measurements and mean value of plasma TG turnover 
rate (VTO) In normolipldemlc subjects (N), subjects with familial combined hyperllpldemla 
(FCH), subjects with familial hypertriglyceridemia (FHT) and subjects with unclassified 
hypertriglyceridemia (UNC). 
Plasma TG turnover rate was positively correlated with plasma TG concen­
tration in the normal controls (r=0.72, p<0.01) and in the subjects with 
FCH (r=0.56, p<0.01) but not in patients with FHT (r=0.33, ns). The 
relationship between plasma TG turnover rate and TG concentration in both 
genetic groups is depicted in figure 3. Plasma TG turnover rate is increased in 
the majority of the patients, but it is evident that both groups are not 
homogeneous. Although there seems to be a tendency of plasma TG 
concentration in FCH to be somewhat higher in relation to the TG turn­
over rate than in FHT, there is a wide overlap in individual results of both 
groups. 
The mean fractional catabolic rate was equally decreased in all groups with 
hypertriglyceridemia. Both in FCH and in FHT the fractional catabolic rate 
was inversely correlated with plasma TG concentration (FCH: r = - 0 . 6 3 , 
p<0.01; FHT: r = - 0 . 7 5 , p<0.01). This correlation was not present in the 
normal controls ( r = - 0 . 2 4 , ns). 
Neither the fractional catabolic rate nor the plasma TG turnover rate were 
correlated with postheparin LPL activity in either group. The plasma TG 
turnover rate did correlate also neither with plasma HDL-cholesterol nor 
with the relative amounts of the various VLDL-apoC proteins in the different 
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Figure 3. Relationship between turnover rate and concentration of plasma TG In 
subjects with familial hypertriglyceridemia (FHT) and subjects with familial combined 
hyperlipldemla (FCH). 
groups. In subjects with FCH the fractional catabolic rate was positively 
correlated with HDL-cholesterol concentration (r=0.63, p<0.01), but not in 
subjects with FHT (r=0.32, ns). 
DISCUSSION 
In agreement with previous studies,5 2 4 FCH occurred more frequently than 
FHT in our hypertriglyceridemic patients. It has been suggested that elevated 
VLDL levels have a different impact on the risk of premature atherosclerosis 
in subjects with FCH compared to subjects with FHT. 6 It seemed therefore 
of interest to study the underlying metabolic defects of these genetic disor­
ders, in search for a specific metabolic marker which could discriminate 
subjects with FCH from those with FHT among patients with primary 
hypertriglyceridemia. 
HDL-cholesterol, which is inversely correlated with the risk of atherosclero­
sis,2"4 was decreased in both genetic groups to the same extent. The negative 
correlation between HDL-cholesterol and (VLDL-)TG concentration, as 
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found in normals and in both hypertriglyceridemic groups in this study, is 
well known2,25 and indicates that HDL is associated with plasma VLDL 
metabolism in FCH as well as in FHT. A positive correlation has been 
reported between HDL-cholesterol and adipose tissue LPL in normal sub-
jects.26 HDL-cholesterol correlated also positively with postheparin LPL27·28 
and the fractional catabolic rate of both endogenously labeled TG27 and of 
exogenous fat28 in normal subjects. These results suggest, as Nikkilä has 
postulated,29 that the rate of catabolism of TG-rich lipoproteins by the action 
of LPL determines the concentration of HDL-cholesterol in normolipidemic 
subjects. Rapid clearance of TG-rich lipoproteins by LPL would increase 
HDL-cholesterol, whereas a defective catabolism of TG-rich lipoproteins 
would lower HDL-cholesterol. We found also in subjects with FCH a 
positive correlation between HDL-cholesterol and postheparin LPL and 
between HDL-cholesterol and the fractional catabolic rate of plasma TG. 
However, despite the fact that plasma TG turnover rate was increased in our 
study in the majority of these subjects as well as in subjects with FHT, HDL-
cholesterol concentrations were low in these subjects. The explanation for 
this remains obscure. 
The VLDL-cholesterol/VLDL-TG ratio can be used as an indirect estimate 
of VLDL remnants, a high ratio meaning relatively many remnants;15 this 
ratio was similar in both genetic groups and did not differ significantly from 
normal males. The concentrations of LDL-cholesterol and the ratio LDL-/ 
HDL-cholesterol, which are associated with an increased risk of atheroscle-
rosis, were higher in subjects with FCH than in those with FHT, but these 
differences just failed to be significant. However, the ratio LDL-/HDL-
cholesterol in subjects with FCH was significantly higher than in normal 
males, whereas this ratio in subjects with FHT did not differ significantly 
from normals (table 2). This observation could provide an explanation for 
the difference in cardiovascular risk of both disorders. 
Postheparin LPL was not significantly decreased in the various hypertriglyce-
ridemic groups. From reports of familial LPL deficiency it is evident that 
LPL is a key-enzyme in the catabolism of plasma TG.20-30 A subnormal 
activity of LPL has also been reported in primary hypertriglyceridemia both 
in postheparin plasma and in adipose tissue.31-32 On the other hand, normal 
LPL activity has been found in patients with primary hypertriglycerid-
emia.30,31 There is one report on LPL activity in adipose tissue in genetically 
defined hypertriglyceridemic subjects.30 These authors found in five subjects 
with FCH and five subjects with FHT normal amounts of enzyme both in the 
fasted and in the fed state. Thus, plasma TG does not seem to be a simple 
function of LPL activity as is also evident from the poor correlations between 
LPL activity and plasma TG concentration, fractional catabolic rate or 
absolute turnover rate of plasma TG as found in our study. Only in subjects 
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with FHT we found a significant inverse correlation between LPL activity 
and plasma TG concentration 
Impaired clearance of plasma TG may be caused by more than one mecha­
nism such as disturbances in the interaction between substrate and enzyme, 
in the re-estenfication and storage of TG in adipose tissue or the presence of 
inhibitors of LPL in the plasma A regulatory role has been ascribed to the 
ratio of apoC-H/C-HI in the removal of plasma TG 1 3 1 4 However, the VLDL 
apoC composition was similar in both genetic groups No abnormalities could 
be detected in the ratio of apoC-II/C-III or the relative amounts of ароС-ІІІ! 
and apoC-IIb in the various groups Only subjects with FHT had slightly but 
significantly higher relative amounts of the non sialylated form of apoC-III, 
apoC-III0, compared with the control group Falko et al
33
 reported an 
increase in apoC-III,, after a carbohydrate-rich diet in normal and hyperhpid-
emic subjects, these authors suggested that the increase of apoC-III0 caused 
by this diet, might be explained by an increase in the secretion rate of VLDL, 
resulting in a shortened residence-time of VLDL in the Golgi apparatus of 
the liver cells, where sialylation of apoC-III occurs, at least in rats M From 
these observations one could expect a correlation between plasma TG 
turnover rate and apoC-III,, However, apoC-III0 did correlate neither in this 
study with plasma TG turnover rate in the various groups nor in the whole 
group of all hypertnglycendemics together 
The validity and limitations of the method used to determine plasma TG 
turnover rate during a relatively short period has been discussed extensi­
vely9 2tl " 36 (chapter II) Plasma TG turnover rate was found to be increased 
in the majority of our patients, thus, hypertriglyceridemia appears mainly to 
be due to oversecretion of plasma TG in both genetic groups However, in 
some subjects of both groups hypertriglyceridemia must be caused by an 
impaired removal (figures 2 and 3) The observed inverse correlation 
between fractional catabohc rate and plasma TG concentration does not 
need to argue in favor of the role of impaired removal, but can be explained 
by the known saturability of the plasma TG removal mechanism,22 " causing 
a decrease in the percentage of the plasma TG pool which is cleared per unit 
of time with increasing pool size So far, only a limited number of kinetic 
studies has been published of genetically well defined hyperhpidemic sub­
jects 7"9 An overproduction of both plasma TG and VLDL-apoB has been 
found in the majontv of patients with FCH and FHT 7 9 Only Janus et al 
reported normal VLDL-apoB turnover rates in three subjects with FHT 8 
Thus, our results as well as most of the evidence from the literature point to a 
major role for overproduction of plasma TG m the pathogenesis of both 
disorders, but it should be emphasized that both disorders are not homoge­
neous 
It has been concluded that hypertriglyceridemia in FHT is caused by an 
% 
oversecretion of TG-enriched VLDL, whereas that of FCH is due to overse-
cretion of VLDL of normal composition.7-9 This was based on combined 
studies of turnover rates of plasma TG and VLDL-apoB in a limited number 
of subjects, including FCH-subjects with the type II phenotype. Differences 
in VLDL composition, namely higher ratios of VLDL-TG/VLDL-apoB and 
VLDL-TG/VLDL-cholesterol in subjects with FHT than in those with FCH, 
supported this conclusion. The percentage of conversion of VLDL-apoB to 
LDL-apoB has been reported in subjects with FCH to be similar to that in 
normal subjects, whereas this percentage of conversion was decreased in 
subjects with FHT.9 It was suggested that the resulting increased LDL 
production in FCH may account for the higher cardiovascular risk in this 
disorder than in FHT.9 This conclusion may be valid concerning the distinct 
genetic groups as a whole (thus including subjects with the type II phenotype 
in the group with FCH), but it remains in question whether this is also true 
when comparing subjects with the type IV phenotype of both groups only. In 
our much larger group of subjects with the type IV phenotype, the difference 
in plasma TG turnover rate was not significant between the genetic groups. 
Furthermore, the ratio of VLDL-TG/VLDL-cholesterol was equal in both 
genetic groups. This ratio was also similar in a great number of subjects of 
both groups (23 subjects with FHT and 47 subjects with FCH) in the original 
report by Hazzard et al.38 
In conclusion, no specific metabolic marker was found that could discrimi-
nate FCH and FHT in subjects with hypertriglyceridemia. Also, we did not 
find clear differences in the metabolic variables studied between the groups 
of subjects with hypertriglyceridemia on different genetic basis. The LDL-/ 
HDL-cholesterol ratio was significantly higher in subjects with FCH, but not 
in those with FHT, than in normals and this might explain the difference in 
risk of cardiovascular disease. Thus, for the time being, family investigation 
remains necessary to identify the familial forms of hypertriglyceridemia. 
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SUMMARY 
The mechanism of hypertriglyceridemia was studied in 26 patients with 
maturity-onset diabetes, treated with diet alone or with diet plus oral 
hypoglycemic agents. Insulin resistance was on the average considerably 
increased. Mean plasma TG turnover rate was increased (15.1±5.4 vs 
9.9±3.0 μιηοΙ.Ι^'.ΐΓ 1 in controls) but in several patients with normal plasma 
TG turnover rate hypertriglyceridemia must be due to impaired plasma TG 
removal. Plasma TG turnover rate did neither correlate with plasma insulin 
concentrations or insulin resistance nor with relative bodyweight, but a 
significant positive correlation was found with the mean of 5 fasting blood 
glucose concentrations (r=0.41, ρ < 0.05). Lipoprotein lipase activity in 
postheparin plasma was in the normal range. 
Treatment with insulin during a mean period of 7.1 weeks (range 3-13 weeks) 
produced divergent effects on plasma TG kinetics. In one group (7 subjects) 
which had the poorest diabetic control plasma TG turnover rate decreased to 
normal, closely correlated with the decrease in plasma glucose levels (r=0.92, 
ρ < 0.01) and inversely with the increase in plasma insulin concentrations 
( r=-0 .88, ρ < 0.01), resulting in a normalization of the mean plasma TG 
concentration. In a second group (8 subjects) plasma TG turnover rate 
remained unchanged, but plasma TG decreased, apparently by improved TG 
removal. This was not accompanied by a significant increase in postheparin 
LPL activity (6.0±2.9 vs 7.0±2.0 цтоі F F A . m r ' . h 1 ) . Plasma TG turnover 
rate was less well correlated with diabetic control in this group, but signifi­
cantly with the mean of the diurnal insulin pattern (r=0.81, ρ < 0.05). In a 
third group (6 subjects) which had a high mean relative bodyweight and 
plasma insulin concentration, insulin treatment had no beneficial effect on 
plasma TG concentration and different patterns in plasma TG turnover rate 
were seen. 
In the whole group mean plasma HDL-cholesterol concentration was low 
and was not increased by insulin therapy (1.00 vs 1.03 mmol/1). HDL-
cholesterol was not correlated with plasma glucose levels. In the group of 
patients with improved TG removal there was a small but significant increase 
in HDL-cholesterol. 
It is concluded that the mechanism of hypertriglyceridemia in maturity-onset 
diabetes is heterogeneous and that treatment with insulin has divergent 
effects on plasma TG metabolism. Despite the presence of moderate degrees 
of obesity, treatment with insulin can be beneficial in patients with maturity-
onset diabetes and hypertriglyceridemia who do not reach desirable weight 
or "good" diabetic control on diet alone or diet plus oral hypoglycemic 
agents. 
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INTRODUCTION 
Cardiovascular disease is the major cause of morbidity and mortality in 
diabetes mellitus.1 Disturbances in lipid metabolism are common in diabetes 
and may play a major role in the development of accelerated atherosclero-
sis.2 Particularly in maturity-onset diabetes (MOD) increased plasma trigly-
ceride (TG) and reduced high density lipoprotein (HDL)-cholesterol con-
centrations are frequently present.3-9 An association between hypertrigly-
ceridemia in diabetics and macrovascular complications has been repor-
ted,310 whereas HDL-cholesterol is negatively correlated with the risk of 
atherosclerosis." Hypertriglyceridemia in diabetes appears to be related to 
metabolic control,12"14 but the influence of diabetic control on HDL-choleste-
rol is less clear.6-9 
The mechanism of hypertriglyceridemia in human diabetes is still the subject 
of controversy: increased production of very low density lipoprotein 
(VLDL)-TG and decreased clearance of VLDL-TG secondary to deficiency 
of lipoprotein lipase (LPL), have been claimed to be the underlying 
defects.15"20 After a certain period of absolute lack of insulin in experimental 
diabetes hypertriglyceridemia is caused by defective TG removal from 
plasma.21 The pathogenesis of hypertriglyceridemia in MOD is more compli-
cated, because the disturbed carbohydrate metabolism is frequently accom-
panied by insulin resistance resulting in elevated insulin levels.22 A positive 
relation between plasma insulin and TG concentration has been frequently 
reported, but the exact role of insulin in regulating TG synthesis remains in 
question.23 
In the present study we have examined a group of patients with non-insulin-
dependent diabetes, who were hypertriglyceridemic despite treatment with 
diet alone or diet plus oral hypoglycemic drugs. The underlying mechanism 
of hypertriglyceridemia was studied in relation with plasma glucose and 
insulin concentrations and insulin resistance. Furthermore, we evaluated the 
effect of treatment with exogenous insulin in an attempt to improve diabetic 
control and to overcome possible insulin insensitivity. A beneficial effect of 
insulin administration on lipid metabolism (lowering plasma TG and increas-
ing HDL-cholesterol) could have implications for the choice of therapy since 
many middle-aged patients are maintained on diet therapy with or without 
oral agents even though their blood sugars and plasma TG remain considera-
bly elevated. 
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MATERIALS AND METHODS 
Patients 
From the outpatients' department for internal medicine 26 patients were 
selected on the ground of the coexistence of MOD, not treated with insulin, 
and hypertriglyceridemia and their willingness to cooperate in the investiga-
tions. Before treatment with diet with or without oral hypoglycemic agents 
they had been overtly diabetic (fasting plasma glucose > 8.0 mmol/1). The 
mean duration of the diabetes before this trial was 7.2 years (range 0.5-23 
years). Hypertriglyceridemia was defined as fasting plasma TG concentra-
tions above 2.0 mmol/1 on several occasions during treatment of the diabetes 
with diet alone or in combination with oral hypoglycemic agents. All patients 
had type IV hyperlipoproteinemia (HLP). There were 12 male and 14 female 
patients. Thirteen patients were on diet alone, twelve used sulphonurea and 
one phenformin in addition. Their mean age was 56.7 years (range 46-67 
years) and their mean relative bodyweight (RBW) was 125% (range 101-
158%), as calculated from mean ideal bodyweight for height from Geigy 
Scientific Tables. None of the subjects had clinical or biochemical evidence 
for thyroid, renal or hepatic disease or alcoholism. They were not taking 
drugs known to affect carbohydrate or lipid metabolism in addition to the 
oral hypoglycemic agents, except for three subjects who took beta-adrenergic 
blocking agents for hypertension and one patient who used furosemide for 
mild congestive heart failure in the past. This medication was not altered 
throughout the study. The patients used a sugar-free diet existing of approxi-
mately 45% of calories from carbohydrates, 40% from fat and 15% from 
protein. 
Experimental design 
The patients were not hospitalized during the study. Before the institution of 
insulin therapy the following protocol was carried out: a) determination of 
fasting plasma glucose and TG concentrations (5 times); b) diurnal patterns 
of plasma glucose and insulin concentrations (blood samples at 8.00, 11.00, 
15.00 and 21.00 hours); c) measurement of the insulin resistance by the 
method of Reaven and co-workers;24 d) postheparin plasma LPL and hepatic 
lipase activity in 23 patients, in 19 patients on two different occasions; e) 
estimation of plasma TG turnover rate after a pulse injection of 2-3H-
glycerol. Before the start of this experiment blood was sampled for the 
determination of fasting glucose, insulin, TG in whole plasma and VLDL 
fraction and cholesterol in whole plasma, VLDL-, low density lipoproteins 
(LDL)-, and HDL fractions. 
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Then insulin therapy (MC Monotard1*, Novo), one injection daily before 
breakfast, was instituted and oral hypoglycemic agents, when used, were 
discontinued. The diet remained unchanged. All patients were seen weekly 
by a physician experienced in treating diabetes. The dose of insulin was 
increased stepwise until satisfactory control was obtained as judged by 
glucosuria and plasma glucose levels or until the patient complained of 
hypoglycemic attacks or a dose of 60 U per day was reached. The mean 
maximal daily insulin dose that was reached amounted to 33 U (range 8-
60 U). Subsequently, the protocol was repeated except for the measurement 
of insulin resistance. The mean duration of insulin therapy before the second 
determination of LPL activity was 5.1 weeks (range 3-9 weeks) and before 
the second measurement of plasma TG turnover rate 7.1 weeks (range 3-13 
weeks). 
Informed consent was obtained from all investigated subjects and the proto­
col was approved by the University Hospital's Ethical Committee. 
Methods 
All blood samples were obtained after an overnight fast, unless otherwise 
stated. Plasma glucose was measured by an automated method;2'' plasma TG 
was determined with a semi-automated method;2 6 plasma lipoproteins were 
separated by preparative ultracentnfugation as described previously;27 chol­
esterol was determined with an enzymatic method.2 8 Plasma insulin was 
measured by radioimmunoassay.29 
Insulin resistance was measured according to Shen et al24 as follows: after an 
overnight fast the subjects were given an intravenous injection of 5 mg 
propranolol followed in 5 minutes by a continuous infusion of a mixture of 
glucose (6 mg/kg/min), insulin (80 mU/ml), adrenaline (6 μg/min) and propra­
nolol (0.08 mg/min) under ECG and blood pressure monitoring. This solu­
tion was infused into an antecubital vein for a period of 150 minutes via an 
infusion pump. Blood samples were drawn from the opposite arm through a 
needle kept patent by a saline drip. Under these experimental conditions 
endogenous insulin secretion is suppressed and steady-state plasma glucose 
(SSPG) and steady-state plasma insulin (SSPI) levels are achieved between 
90 and 150 minutes.2 4 The suppression of endogenous insulin secretion was 
confirmed by the measurement of plasma C-peptide25 before and during the 
infusion of the solution in 25 patients. A mean (± SD) reduction of 56 ± 15% 
was observed in the mean of three concentrations of C-peptide measured 
during the steady-state period from 90-150 minutes compared with the fasting 
value, despite the presence of appreciable hyperglycemia in several cases. 
Since similar SSPI levels are attained in all subjects and all subjects receive 
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identical glucose loads, the mean of seven plasma glucose concentrations 
measured during the steady-state period from 90-150 minutes is a measure of 
the ability of insulin to dispose of a glucose load A high SSPG level indicates 
insulin resistance, while a low SSPG level signifies insulin sensitivity. An 
example of this test is given in figure 1. This test was not performed in the 
presence of hypertension or ECG abnormalities which precluded the use of 
adrenaline in combination with propranolol, because an appreciable rise in 
blood pressure may result.30 Only in 15 of the 26 patients this test was 
therefore performed. Results of six additional patients with MOD and 
hypertriglyceridemia who did not participate in the trial with insulin therapy 
will also be presented. 
Glucose 
(mmol /I) d 53yrs 
glucose, insulin, 
adrenaline, propranolol 
-11.0 
9.0 
0.20-
Figure 1. Plasma glucose, insulin and C-peptide concentrations In a subject during 
infusion of glucose (6 mg/kg/min), insulin (80 mU/min), adrenaline (6 цд/тіп) and 
propranolol (0.0B mg/mln). Plasma glucose concentration during steady-state Is a 
measure of insulin resistance (see text). 
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Postheparin plasma was obtained in 23 patients after intravenous injection of 
50 U/kg sodium heparin (TromboIiquineR, Organon, Oss, the Netherlands). 
Samples were cooled on ice immediately; plasma was separated by centrifu-
gation at 4°C within 30 minutes and stored at -20°C until assay within the 
following 4 weeks. 
In 15 subjects the selective measurement of LPL in plasma obtained 10 
minutes after injection of heparin, was based on inactivation of extrahepatic 
lipase activity by protamine sulfate as described by Krauss et al.31 The 
extrahepatic lipase activity was calculated as the difference between total and 
protamine-resistant (hepatic) lipase activity. In 8 subjects LPL and hepatic 
lipase activity before and during treatment were measured with the immuno­
chemical method of Huttunen et al12 as described elsewhere33 (chapter VII). 
The lipase activities were expressed as цгпоі FFA released by 1 ml of 
postheparin plasma per hour. Results for normal groups by the two methods 
agreed very well (table 2). The same method was always used in one subject 
before and during insulin therapy. 
Plasma TG turnover rate was assessed according to Farquhar et al34 as 
modified by Nikkilä and Kekki35 (described in chapter II). After an overnight 
fast 50 цСі 2-3H-glycerol (Radiochemical Centre, Amersham, England) was 
administered intravenously as a pulse injection. Plasma TG radioactivity and 
concentration were determined in nine blood samples until 7 hours after 
administration. Plasma TG were extracted according to Royer and Ko3 6 
using η-heptane instead of n-nonane. Fractionation of the lipoproteins during 
this test was omitted for reasons discussed previously35 (chapter II). The 
slope of the fall in specific activity of the endogenously labeled TG with time 
(fractional catabolic rate) was determined by the method of least squares 
analysis. Only mono-exponential curves were accepted and a steady-state in 
plasma TG was required (variation in plasma TG less than 10%). The 
product of the fractional catabolic rate, the mean TG concentration during 
the experiment and the plasma volume gives plasma TG turnover rate. 
Plasma volume was calculated from hematocrit and a nomogram for deriving 
blood volume from height, weight and sex with a correction for overweight.37 
The limitations of this technique for estimating TG turnover during a 
relatively short period have been discussed elsewhere in detail.3 3 , 3 8·3 9 Zech et 
al40 have shown that the assumption of a simple one-pool model to determine 
TG turnover is an oversimplification and that multicompartmental analysis is 
required. They found that after 12-18 hours the fall in specific activity of 
VLDL-TG was not mono-exponential, but a slow tail emerged, ascribed to a 
more slowly turning-over precursor compartment. However, a statistically 
significant relation was found between the two methods of data analysis.41 
Furthermore, with the use of other techniques similar values for TG turnover 
have been reported compared with the glycerol method as used in the present 
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study.42 ^ As discussed by Tobey et al this way of estimation of TG turnover 
may be incorrect in absolute terms, the relative differences between the 
individual subjects are probably valid irrespective of method of data analysis 
(see chapter II). 
Statistics 
Statistical methods used were Student's t-test and Wilcoxon's test for paired 
and unpaired data and the correlation coefficient according to Pearson. P-
values less than 5% were considered to be significant. Results are expressed 
as mean ± SD. 
RESULTS 
Plasma lipids, glucose, insulin and bodyweight 
The results for plasma lipids, glucose and insulin concentrations before and 
during insulin therapy are summarized in table 1. There was a significant 
decrease in the mean concentrations of plasma glucose (mean of 5 fasting 
values and of diurnal pattern), plasma TG (mean of 5 fasting values) and 
VLDL-TG. Plasma insulin concentration increased. So, on the average, 
diabetic control was significantly improved and plasma TG decreased, 
although this was not true for every individual patient. In 16 out of the 26 
patients plasma glucose concentrations decreased by 20% or more (mean of 5 
fasting values or of diurnal pattern) or were below 8.0 mmol/1 during insulin 
therapy. Of these 16 subjects 9 were treated before with diet alone, 7 with 
oral agents in addition. In 2 subjects diabetic control was worsened. These 
subjects were very obese (RBW 150 and 143%, respectively). In 15 out of the 
26 patients plasma TG concentrations decreased by 20% or more (mean of 5 
fasting values); in one subject (RBW 143%) fasting plasma TG increased. In 
10 patients both plasma glucose and TG concentrations decreased by 20% or 
more. During the period of insulin treatment the mean rise in bodyweight 
was 0.9 kg (75.1 ±9,2 vs 76,0±9,9 kg, ρ < 0.01). 
The mean concentrations of total plasma cholesterol, VLDL-, LDL- and 
HDL-cholesterol did not change significantly. The VLDL-cholesterol/ 
VLDL-TG ratio was also not altered by insulin treatment. HDL-cholesterol 
concentration in this group was lower than normal (mean value for 28 normal 
men 1.29 ± 0.28 mmol/1, for 40 normal women 1.48 ± 0.35 mmol/1). There 
was no significant inverse correlation between HDL-cholesterol and VLDL-
TG concentration in this group (r = -0.28 before and r = -0.32 during insulin 
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Table 1. Plasma glucose, Insulin and lipid concentrations In 26 patients with maturity-
onset diabetes and hypertriglyceridemia before and during insulin therapy. Results are 
presented as mean ± SD. 
glucose (mmol/l) 
mean of 5 x fasting 
mean of diurnal pattern* 
insulin Сци/ті) 
fasting 
mean of diurnal pattern** 
triglycerides (mmol/l) 
mean of 5 x fasting 
VLDL 
cholesterol (mmol/l) 
total 
VLDL 
LDL 
HDL 
before 
10.9 
11.9 
21 
33 
4.13 
3.45 
6.90 
1.87 
3.91 
1.01 
+ 
± 
± 
+ 
± 
± 
+ 
+ 
+ 
± 
3.4 
4.0 
17 
20 
2.21 
2.92 
1.37 
1.00 
1.03 
0.27 
during 
8.9 
9.7 
27 
43 
3.28 
2.43 
6.59 
1.55 
4.12 
1.03 
+ 
± 
± 
+ 
+ 
± 
± 
± 
± 
± 
2.1 
3.1 
20 
21 
2.09 
1.92 
1.17 
1.07 
1.23 
0.25 
Ρ 
< 0.002 
< 0.003 
ns 
< 0 . 0 1 
< 0.001 
< 0 . 0 3 
ns 
0.07 
ns 
ns 
' Mean of blood samples at 8.00, 11.00, 15.00 and 21.00 hours 
' 22 subjects 
therapy). Nor were significant correlations found between HDL-cholesterol 
and concentrations of plasma glucose (mean of fasting and diurnal pattern) 
or plasma insulin (mean of fasting and diurnal pattern). 
Insulin resistance 
In patients with MOD and hypertriglyceridemia mean insulin resistance was 
significantly higher than in a non-diabetic control group (p < 0.001, fig. 2). 
The results for the six additional patients who did not participate in the other 
investigations, fitted well in this group; their mean insulin resistance (SSPG) 
was 10.8 mmol/l (range 4.9-18.1 mmol/l). As is shown in figure 2, there was 
an overlap of SSPG in this group of patients with the results obtained in 
normal controls. Several of the latter subjects, very sensitive for insulin, 
reached the hypoglycemic area, where it can be expected that contraregula-
tory mechanisms prevent further decrease in plasma glucose. The real 
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difference in insulin resistance between both groups may therefore have been 
even greater. The mean insulin resistance in the hypertriglyceridemic dia­
betics was also significantly higher than in a group of 9 non-diabetic patients 
with type IV HLP (p < 0.01) and of normolipidemic patients with MOD (p < 
0.03). Insulin resistance in the latter two groups was also significantly higher 
than in the normal control subjects (p < 0.05). All groups had comparable 
mean relative bodyweights except for the mean RBW in both diabetic groups 
which differed significantly (p < 0.05, fig. 2). In the group of MOD + type 
IV HLP, insulin resistance was positively correlated with RBW (r=0.54, ρ < 
0.05). Insulin resistance and fasting insulin concentrations were positively 
correlated only when the results of all subjects of the different groups were 
analyzed together (n=52, r=0.45, ρ < 0.001). In the group of patients with 
MOD and type IV HLP no significant correlations were found between 
insulin resistance and fasting plasma insulin levels (n=21, r=0.27) or mean of 
diurnal insulin pattern (n=15, r=0.31). Insulin resistance was neither signifi­
cantly correlated with the maximal dose of insulin achieved (n=15, r=0.44) 
nor with the mean fasting TG concentrations (n=15, r=0.43). 
s.s.glucose 
(mmol/ I) 
2 4 η 
20 - · o b e s e * 
· · 
Ιο­
ί 
12- . _!1 
• -L 8 
! Г : 
Ñ Ш MOD MOD+Ш 
number 1A 9 θ 21 
RBW% 114113 11 +Ю 110±10 120115 
Figure 2. Steady-state glucose as measure of Insulin resistance (Individual values and 
mean) In normal subjects (N), non-dlabetlc patients with type IV hyperlipoproteinemia 
(IV), normolipidemic diabetics (MOD) and diabetics with type IV hyperlipoproteinemia 
(MOD + IV). Mean ( ± SD) relative bodyweight of the different groups Is given. Obese 
patients are indicated. 
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Postheparin lipolytic activities 
Data of postheparin LPL and hepatic lipase activity in 23 patients before and 
during insulin therapy are summarized in table 2. In most patients the mean 
of two samples was taken. Both in male and female diabetic patients lipolytic 
activities were in the normal range. LPL was neither correlated with plasma 
TG concentrations (r=-0.27, n=23) nor with fasting insulin concentration 
(r=-0.22, n=23), nor with insulin resistance (r=0.33, n=13). Insulin 
therapy did not produce significant changes in LPL and hepatic lipase 
activities. 
Table 2. Postheparin plasma lipolytic activities in 23* patients with maturity-onset 
diabetes and hypertriglyceridemia before and during insulin therapy. Results are mean 
± S D . 
patients 
males (n=9) 
females (n=14) 
controls 
males (n=22)** 
females (n=25)** 
males (n=14)*** 
females (n=15)*** 
LPL 
(μπιοί FFA ml ' • h" 1) 
before 
6.2 ± 3.3 
6.9 ± 2.3 
6.3 ± 2.4 
8.6 ± 3.6 
8.0 ± 2.5 
8.9 ± 2.2 
during 
6.3 ± 2.6 
8.0 ± 2.7 
hepatit 
(μπιοί FFA 
before 
26.8 ± 10.7 
22.2 ± 7.6 
25.1 ± 6.7 
16.8 ± 6.3 
25.9 ± 9.1 
16.2 ± 6.4 
: lipase 
• ml-' - h" 1) 
during 
25.3 ± 12.7 
20.1 ± 5.7 
* In 3 of the 26 patients not analyzed 
" protamlne-lnhlbltlon method 
"* Immunochemical method 
Plasma TG turnover rate 
The results of the measurement of plasma TG turnover rate before insulin 
therapy are presented in table 3. One of the 26 experiments had to be 
rejected because of an insufficient steady-state in plasma TG. Mean plasma 
TG turnover rate was increased and comparable with results obtained in non-
diabetic subjects with type IV HLP. Fractional catabolic rate was in both 
groups decreased (table 3). In the diabetic group plasma TG turnover rate 
was clearly elevated in 11 subjects, in the high normal range in 9 subjects and 
normal in 5 subjects. Plasma TG turnover rate was positively correlated with 
plasma TG concentrations in the diabetic subjects (r=0.63, ρ < 0.001). A 
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Table 3. Plasma triglyceride (TG) concentration, fractional catabollc rate (FCR) and 
plasma TG turnover rate In patients with maturity-onset diabetes (MOO) and hypertrigly­
ceridemia (HTG) compared with control groups. Results are presented as mean ± SO. 
MOD + HTG 
HTG subjects 
healthy controls 
η 
25 
16 
17 
Rel. 
(%) 
124 
123 
118 
we 
± 
± 
+ 
ight 
16 
10 
19 
Plasma TG 
(mmol/1) 
3.10 ± 
3.83 ± 
1.09 ± 
1.09** 
1.35** 
0.33 
FCR 
(h ') 
0.14 
0.14 
0.26 
+ 
± 
+ 
0.05** 
0.05** 
0.06 
Plasma TG 
tuinover rate 
(μπιοί 
15.1 
17.1 
9.9 
• kg ' · h ') 
± 5.4** 
± 6.3** 
± 3 . 0 
* mean of 9 samples during the study period 
" ρ < 0.001 versus healthy controls 
significant positive correlation was found between plasma TG turnover rate 
and the degree of diabetic control as estimated by the mean of 5 fasting 
glucose concentrations (r=0.41, ρ < 0.05) and the mean of diurnal glucose 
pattern (r=0.40, ρ < 0.05). No correlation was found between plasma TG 
turnover rate and plasma insulin levels (fasting insulin concentration: 
r=0.11 and mean of diurnal insulin pattern r=-0.06) nor between plasma 
TG turnover and insulin resistance (n=14, r=0.13). Plasma TG turnover 
or fractional catabolic rate were not correlated with LPL activity (n=23, 
r=0.20 and r=0.16, respectively). Furthermore, plasma TG turnover rate 
was not correlated with relative bodyweight (r=0.2()). 
After treatment with insulin, measurement of plasma TG turnover was 
repeated in the 26 patients; experiments of 4 patients had to be rejected 
because of an insufficient steady-state in plasma TG concentration. So, in 21 
patients the effect of treatment with insulin on plasma TG turnover rate 
could be studied. Insulin therapy produced divergent effects on plasma TG 
turnover rate and distinct groups could be identified: group I consisting of 7 
patients characterized by a decrease in plasma TG as a result of a fall of more 
than 15% in plasma TG turnover rate (fig. 3); group II consisting of 8 
patients, in whom hardly any change (less than 15%) in plasma TG turnover 
rate was found, but yet plasma TG concentration had decreased, apparently 
by an improved plasma TG removal (fig. 4). The limit of 15% was chosen, 
because it had appeared that at similar plasma TG concentrations the 
measurement of plasma TG turnover was reproducible within 10% (chapter 
II). In the remaining 6 patients (group III) plasma TG concentration was 
either unchanged or increased and different patterns were found in plasma 
TG turnover rate by insulin therapy: decrease in one subject, no change in 2 
subjects and increase in 3 subjects. Table 4 summarizes some characteristics 
of these groups. 
Group I had the lowest diurnal insulin concentration and the poorest diabetic 
control. The mean dose of insulin reached in these patients was 38 U/day 
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V T G 
plasma TG (mmol /1 ) 
Figure 3. Plasma TG turnover rate (VTa) before (o) and during ( · ) Insulin therapy In 
relation with plasma triglyceride (TG) concentration in group I. Small dots represent 
normollpldemlc controls. 
V T G 
(/umol. kg- 1 . h-1 ) 
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group I I 
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2 3 A 5 
plasma TG (mmol/ l ) 
Figure 4. Plasma TG turnover rate (
 т а
) before (o) and during ( · ) Insulin therapy In 
relation with plasma triglyceride (TG) concentration In group II. Small dots represent 
normollpldemlc controls. 
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Table 4. Metabolie characteristics and relative bodyweight (RBW) of groups I, II and III 
before and during insulin therapy. The maximal dose of Insulin reached during therapy Is 
given. Results are mean ± SD. 
GROUP [ (n = 7) GROUP [I (n = 8) GROUP III (n=6) 
before dunng before during before during 
glucose (ттоШ) 
mean of 5 χ fasting 13 2±4 3 8 7±15" 9 7±17 9 4±2 6 9 8±2 3 86+20* 
mean of diurnal pattern 15 0+5 6 10 8±4 3* 10 3±2 5 9 0±2 9* 11012 6 9 3 + 2 3 
insulin ftiU/ml) 
fasting 14±7 24±15 17±7 16±9 38±29 45 + 23 
mean of diurnal pattern 19±8" 3β±20" 28±13 33±19 50+23 60+25 
TG (mmolll) 
mean of 5 χ fasting 2 94±0 94 19910 37· 3 751156 2 69+0 98* 5 17+3 23 4 65 + 3 06 
HDL-choleslerol 123+0 22 11310 27 10010 30 11210 31" 0 ^ + О 18 0 86+0 13 
(mmol/l) 
LPL 7 7 + 2 5 7 6+2 5 6 0+2 9" 7 012 0" 6 7+3 2 6 1+2 6 
(\unolFFA тГ' h'1) 
RBW(%) 121 + 11 123111* 118115 119+19 130+16 133118* 
Maxmal dose of insulin 38 + 13 32113 3 1 + 2 
fUlday) 
* ρ < 0.05 In comparison with value before Insulin therapy. *6 subjects "7 subjects 
(range 24-60 U). Insulin therapy caused a significant increase in mean diurnal 
insulin concentration and a marked improvement of diabetic control. The 
change in plasma TG turnover rate correlated well with the decrease in 
fasting glucose levels (r=0.92, ρ < 0.01) and was inversely correlated with 
the increase in fasting insulin concentrations ( r=-0.88) , p<0.01). The 
decrease in the mean fasting TG concentrations was also positively correlated 
with the decrease in the mean fasting glucose concentrations (r=0.87, ρ < 
0.05). SSPG was measured in this group only in 3 of the 7 patients and 
amounted to 7.5, 9.4 and 21.9 mmol/l, respectively. Four of the 7 patients had 
been treated with sulphonurea before insulin therapy. 
In group II diabetic control improved hardly on insulin therapy. Only the 
mean of the diurnal glucose pattern decreased significantly. The mean dose 
of insulin amounted to 32 U/day (range 8-52 U). Insulin concentrations were 
not increased despite insulin administration. Although fractional catabolic 
rate increased considerably (from 0.14 ± 0.04 to 0.21 ± 0.05 h"1), 
postheparin LPL activity was not increased (table 4). The increase in 
fractional catabolic rate was not correlated with the change in the mean of 
diurnal glucose concentrations (r=0.20). The decrease in the mean fasting 
TG concentrations was not correlated with the change in the mean of diurnal 
or fasting glucose concentrations. HDL-cholesterol concentration increased 
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Table 5. Correlation coefficients between plasma TG turnover rate and various metabo­
lic variables before and during Insulin therapy In group I and II. 
variable 
TG' 
Glucose 
mean 5 χ fasting 
mean of diurnal pattern 
Insulin 
mean of fasting 
mean of diurnal pattern 
correlation 
before 
0 73 
0 85 
0 85 
-0 16 
-0 26 
GROUPI(n = 7) 
ρ correlation 
during 
<0 10 0 27 
>0 05 
<0 05 0 06 
<0 05 0 02 
ns -0 23 
ns 0 06· ' 
ρ 
ns 
ns 
ns 
ns 
ns 
correlation 
before 
0 70 
0 54 
0 73 
0 43 
081 — 
GROUP И (n=8) 
ρ correlation 
during 
<0 10 0 78 
>0 05 
ns 0 84 
p<0 05 0 92 
ns 0 49 
p<0 05 0 9 6 " 
ρ 
<0 05 
<0 01 
<0 01 
ns 
<0 001 
* mean of 9 samples during the study period 
" 6 subjects 
"* 7 subjects 
in this group significantly. SSPG was measured in this group in 6 of the 8 
patients. The mean SSPG level was 10.4 mmol/1 (range 2.8-20.6 mmol/1). 
Five of the 8 patients had been treated with sulphonurea before insulin 
therapy. 
In group III diabetic control was also not much improved (table 4). These 
patients had the highest mean plasma insulin and TG concentrations and 
RBW and the lowest mean plasma HDL-cholesterol concentration, although 
the differences did not reach the significance level in comparison with group I 
and II. Mean SSPG value of 4 subjects of this group was 12.7 mmol/l (range 
5.8-18.1 mmol/1). Two subjects had been treated before with sulphonurea; 
the maximal dose of insulin in these 6 patients ranged from 28-32 U/day. 
Table 5 demonstrates the relationship between plasma TG turnover rate and 
various metabolic variables in groups I and II. 
When plasma TG kinetics were analyzed in the 16 patients who had a 
decrease of plasma glucose concentration of 20% or more under influence of 
treatment with insulin, divergent effects were also observed. Plasma TG 
turnover rate could be studied before and during insulin therapy in 13 of 
these subjects. A decrease in plasma TG turnover rate was seen in 7 patients, 
unchanged plasma TG turnover rate with decrease in plasma TG concentra­
tion in 4 subjects, increased plasma TG turnover rate with unchanged plasma 
TG concentration in one subject and unchanged plasma TG turnover rate 
and increased plasma TG concentration in another. Of these 13 subjects 7 
had been treated with diet alone and 6 with sulphonurea in addition before 
the institution of insulin therapy. This heterogeneous pattern in the change of 
plasma TG turnover rate was independent of the way of treatment before 
insulin therapy. 
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DISCUSSION 
The mechanism of hypertriglyceridemia in MOD has been controversial. 
Oversecretion of TG has been claimed to be the underlying defect.1516'44 On 
the other hand, it has been suggested, using different techniques, that 
impaired removal is determinant for plasma TG concentrations in untreated 
diabetics, returning to normal during diabetic control.12,18 The mechanism of 
hypertriglyceridemia in our group of patients with MOD and type IV HLP 
appeared to be heterogeneous. The mean plasma TG turnover rate was 
increased and there was a significant positive correlation between TG 
turnover rate and plasma TG concentration. In the majority of our patients 
hypertriglyceridemia seems therefore to be due to oversecretion of plasma 
TG. In the patients with normal plasma TG turnover rate, however, impaired 
plasma TG removal must be the underlying defect. One factor which may 
have contributed to the heterogeneity in the mechanism of hypertriglycerid-
emia in our diabetic patients, is the possible coexistence of familial forms of 
hypertriglyceridemia in some of them.49 
Kissebah et al45 reported normal TG turnover rates in 16 nonobese subjects 
with MOD and elevated secretion rates in 7 obese patients. Although 
overweight is related to plasma TG concentration,46-47 plasma TG turnover 
rate was not correlated with relative bodyweight in our group of patients, 
who were on the average moderately obese. This agrees well with results 
obtained in a large population with a wide range of plasma TG, which 
showed no effects of moderate degrees of obesity on plasma TG turnover 
rate.48 Excess in bodyweight is therefore not solely responsible for increased 
plasma TG concentrations in our patients. 
The significant positive correlation between plasma TG turnover rate and 
plasma glucose concentrations in the whole group of patients suggests that 
poor diabetic control increases plasma TG production and thus influences 
plasma TG concentration. This relationship was not found with plasma 
insulin levels nor insulin resistance. Insulin resistance and hyperinsulinemia 
have been postulated to be causative factors in the development of hypertri-
glyceridemia.40^1 Mean insulin resistance was considerably elevated also in 
our group of patients with MOD and hypertriglyceridemia (fig. 2), but there 
was no correlation with fasting or mean of diurnal insulin concentrations in 
this group as has been reported in normal subjects and subjects with endoge-
nous hypertriglyceridemia.39 5I Therefore, in our patients (as can be expec-
ted in diabetes) insulin concentration is not determined by insulin resistance 
alone. Although a close correlation has been frequently reported between 
plasma insulin and TG concentrations in normal subjects and in patients with 
primary hypertriglyceridemia,52^4 this has not always been found in normal 
subjects23'55,56 and in diabetics.57"59 Thus, the relationship between plasma 
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insulin and TG concentration is complex, in particular in MOD; this is not 
surprising since plasma insulin responses can be low, normal or high in this 
group of patients and insulin has opposing effects in lipid metabolism.60 It is 
therefore also not surprising that our groups of patients appeared to be 
heterogeneous regarding the effects of insulin treatment. 
The relationship between diabetic control and plasma VLDL-TG turnover 
rate becomes in particular evident in group I. This group of patients, with a 
substantial fall in plasma TG turnover rate to the normal range (fig. 3), had 
the poorest diabetic control and lowest plasma insulin levels; no correlation 
was found between plasma TG turnover rate and insulin levels; the decrease 
in plasma TG turnover rate correlated closely with the decrease in fasting 
plasma glucose levels and inversely with the increase with fasting insulin 
levels. In group II plasma TG turnover rate remained unchanged and plasma 
TG must have been decreased by an improved TG removal (fig. 4). In this 
group plasma TG turnover rate correlated less well with diabetic control 
before insulin therapy. Administration of insulin apparently increased 
plasma TG clearance although diabetic control was only improved to a 
limited extent. A significant positive correlation was found in this group 
between plasma TG turnover rate and mean diurnal insulin pattern before 
and during insulin therapy. Insulin therefore may have played an important 
role in determining plasma TG production in this subgroup; exogenous 
insulin may have maintained plasma TG production at the same rate in 
addition to increasing plasma TG clearance. Postheparin LPL activity was 
not decreased before insulin therapy and improved plasma TG removal was 
not accompanied by a significant increase in postheparin LPL activity in this 
group. This will be discussed later. In group III no beneficial effect of 
treatment with insulin on plasma TG levels was seen. Diabetic control was 
also hardly improved. In this group with high insulin concentration and mean 
relative body weight, insulin resistance could apparently not be overcome by 
exogenous insulin administration. 
We did not find a significant increase in postheparin plasma LPL activity in 
our group of patients with improved plasma TG removal during insulin 
therapy. This could be due to shortcomings in methodology, e.g. a higher 
dose of heparin may have discriminated better subjects with subnormal 
amounts of enzyme. On the other hand, after intravenous injection of 
heparin LPL is released from several tissues and increased enzyme activity in 
a specific tissue may be masked by a decrease in another. It has been 
reported thas insulin has opposing effects on LPL from cardiac and adipose 
tissue in rats.01 In untreated insulin-deficient diabetic patients hypertrigly-
ceridemia has been related to subnormal LPL activities in postheparin 
plasma and biopsies of muscle and adipose tissue;20,44 insulin treatment 
resulted in a rapid return of plasma TG and LPL activity to normal. In non-
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insulin-dependent diabetes both subnormal and normal LPL activity has 
been found.17·44·62·63 Also, in primary hypertriglyceridemia LPL activity has 
been reported to be subnormal or normal without any correlation between 
LPL and plasma TG.64,65 Furthermore, in experimental diabetes in rats the 
rise in plasma TG did not correlate with the decrease in tissue LPL acti-
vity.66,67 Thus, plasma TG removal does not seem to be a simple function of 
decreased LPL activity, although it is obvious from reports of familial LPL 
deficiency or deficiency of the specific activator of LPL, apolipoprotein C-II, 
that LPL has a key-role in the clearance of TG-rich lipoproteins.33 Impaired 
clearance may be caused by more than one mechanism such as disturbances 
in the interaction between substrate and enzyme or in the re-esterification 
and storage of TG in adipose tissue or by the presence of inhibitors of LPL in 
the plasma.6869 
In our hypertriglyceridemic diabetics plasma HDL-cholesterol was conside-
rably decreased (table 2). No correlation was found between HDL-choles-
terol and diabetic control. Administration of insulin did not influence HDL-
cholesterol in the whole group. There was a small but significant increase of 
HDL-cholesterol in group II, possibly as a result of increased TG removal, 
because it is supposed that HDL is in part derived from surface products 
released during lipolysis of TG-rich lipoproteins.70 Calvert et al found also an 
increase in plasma HDL-cholesterol after treatment with insulin for 4-12 
weeks in 8 subjects with MOD.8 Paisey et al reported a rise in HDL-
cholesterol at 12 months during treatment with insulin of 6 maturity-onset 
diabetics.71 Lisch and Sailer found a higher HDLi concentration, which is 
supposed to be the anti-atherogenic subfraction of HDL, in MOD patients 
treated with insulin in comparison with subjects treated with sulphonurea.72 
In other reports no correlation between HDL-cholesterol and diabetic con-
trol was found in MOD.7-9 These conflicting results may be explained by the 
heterogeneity of patients with MOD. 
It is obvious, that the primary goal of therapy in patients with MOD and 
hypertriglyceridemia, who are in general moderately obese, should be weight 
reduction, thereby improving diabetic control, decreasing insulin resistance 
and correcting lipid disorders. During treatment with diet alone or oral 
hypoglycemic agents in addition, these patients frequently do not succeed in 
reaching desirable weight nor optimal diabetic control. It can be difficult to 
decide whether or not to institute treatment with insulin; a favorable effect of 
insulin administration on lipoproteins could be an additional reason to start 
this treatment. In our group of patients diabetic control was improved in 60% 
of the patients as estimated from plasma glucose levels. Severe hypoglycemic 
attacks did not occur and weight gain was a problem in only a few patients. 
The present study has shown that insulin treatment can correct plasma 
VLDL-TG production, especially when diabetic control with diet and diet 
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plus oral agents is poor, or it may improve plasma TG removal, despite the 
presence of moderate degrees of obesity. In subjects with more severe 
obesity insulin therapy has no beneficial effects. 
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SUMMARY 
The composition of apolipoprotein С (apoC) of the very low density lipopro­
teins (VLDL) was examined in 23 treated Type 2 (non-insulin-dependent) 
diabetic patients, who had elevated VLDL concentrations. Apolipoprotein С 
was separated by isoelectric focussing in apoC-II, which is known as the 
specific activator of lipoprotein lipase, and apoC-III0, apoC-IIIj and apoC-
I I ^ . A regulatory role has been ascribed to the ratio of apoC-II/C-III in the 
removal of plasma triglycerides. In our diabetic group the composition of 
apoC of the VLDL particles was not different from that of a healthy control 
group. In particular, the ratio of apoC-II/C-III and the relative amounts of 
apoC-IIIo, C-III, and C-III2 were normal. Hypertriglyceridaemia in these 
diabetic subjects does not seem to be related to alterations in the apoC 
composition. 
88 
INTRODUCTION 
Apolipoprotein С (apoC) is a major protein of human plasma chylomicrons 
and very low density lipoproteins (VLDL). ApoC consists of several poly­
peptides, of which apoC-II is the specific activator of lipoprotein lipase. Since 
apoC-III opposes the effect of apoC-II on lipoprotein lipase in vitro, a 
regulatory role has been ascribed to the ratio of apoC-II/C-III in the removal 
of plasma triglycerides.1,2 The role of apoC-III in vivo, however, remains 
uncertain. Apoprotein C-III is a glycoprotein containing 0,1 or 2 mol of sialic 
acid; these peptides are designated C-III0, C-III] and C-III2, respectively. 
Recently, Gabor et al3 reported an increase in the relative amount of apoC-
III, and a consequent decrease in the ratio of apoC-II/C-III, of the VLDL 
fraction in six patients with Type 2 (non-insulin-dependent) diabetes and 
elevated VLDL levels. These authors used Polyacrylamide gel electrophore­
sis in urea (8 mol/1) to quantitate the apoproteins. By this method no 
resolution is obtained of apoC-IIIo- In search of further evidence for a 
possible pathogenetic role for an abnormal VLDL-apoC composition, we 
examined serum samples of 23 patients with insulin-independent-diabetes 
and Type IV hyperlipoproteinaemia, using analytical isoelectric focussing for 
the separation of the apoproteins. 
PATIENTS AND METHODS 
For the purpose of the study 23 patients with diabetes and hypertriglyceridae-
mia (12 males, 11 females) were examined. Their mean age was 57.5 ± 5.9 
years (± SD) and the mean relative bodyweight was 123 ± 14% (calcula­
ted from mean ideal bodyweight for height from Geigy Scientific Tables). 
The mean duration of the diabetes was 7.0 years (range 0.5-23 years). They 
were treated with diet alone (nine subjects) or in combination with sulphonu-
rea (12 subjects) and insulin (two subjects). Normolipidaemic subjects (14 
males, eight females) chosen from healthy hospital personnel served as the 
control group, although their mean age of 37.0 ± 7.3 years and mean 
relative bodyweight of 105 ± 6% were significantly different compared 
with the patients. Plasma was obtained after an overnight fast. The lipopro­
teins were isolated by preparative ultracentrifugation as described previ­
ously.4 Cholesterol was determined with an enzymatic method and triglyceri­
des with a semi-automated colorimetrie method.4 The apoprotein С composi­
tion of the VLDL fraction was determined with isoelectric focussing.5·6 
VLDL was washed by a subsequent ultracentrifugation and delipidated in 
acetone: ethanol (1:1 v/v). After isoelectric focussing the apoproteins were 
stained with Coomassie blue, followed by densitometric scanning. There was 
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a linear relationship between the amount of VLDL apoproteins loaded on 
the gel and the densitometric response.6 No correction was made for higher 
apoC-II chromogenicity.7,8 
Results are expressed as mean ± SD. For statistical analysis Student's t-test 
and the Wilcoxon test for unpaired data were used. 
RESULTS 
Fasting plasma glucose in the diabetic subjects at the time of sampling blood 
for lipoproteins was 11.5 ± 4.3 mmol/1. By selection plasma triglyceride 
concentrations were elevated in the diabetic subjects (Table 1). Chylomi-
crons were not present and plasma LDL-cholesterol concentration was 
normal (<5.2 mmol/1), so that all subjects had Type IV hyperlipoprotein-
aemia. 
The results of the measurement of the relative amounts of the VLDL apoC-
III peptides and the ratio apoC-II/C-III are presented in Table 1. Our results 
for the determination of the VLDL apoC-II/C-III ratio in the normolipidae-
mic group are comparable with those reported by Catapano.7 The distribu-
tion of the variously sialylated forms of apoC-HI in the diabetic group was 
not different from that in the control group. The relative amount of VLDL 
apoC-III) was not increased. Also, the ratio apoC-II/C-III was not decreased. 
Table 1. Plasma triglyceride concentration (total and in the VLDL fraction), distribution 
of apoprotein C-lll subspecies and apoprotein C-ll/C-lll ratio in VLDL from hypertriglyce-
rldaemlc diabetic patients and normal subjects. 
triglycérides (mmol/]) 
total 
Diabetic patients 3 60 ± 1 12* 
(n - 23) 
Control subjects 1 04 ± 0.38 
(n = 22) 
VLDL 
2.80 ± 1 02* 
0 55 ± 0 29 
C-I7I„ С-Ш, C-III. 
№ of total VLDL apoC-III) 
18 9 ± 4 6 44 8 ± 5 5 36 1 ± 5.2 
17.2 ± 5 3 44 4 ± 3 . 6 38 7 ± 3 8 
apoC-Il'C-lll 
0 19 ± 0 07 
0.18 ± 0.07 
Results are presented as mean ± SD 
* ρ < 0.001 versus control subjects 
DISCUSSION 
In primary Type IV hyperlipoproteinaemia normal apoC-II/C-III ratios have 
been reported by Schonfeld et al9 both in total plasma and VLDL fraction 
(assessed by radioimmunoassay) and by Kashyap et al8 (as measured by 
isoelectric focussing). The latter authors found only in Type V patients a 
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significantly higher content of apoC-III,, and lower content of apoC-IIIo of the 
d<1.006 g/ml fraction. Catapano7 reported decreased ratios of apoC-II/C-
III in Type IV patients (by isoelectric focussing), as has been found by 
Carlson and Ballantyne1 using Polyacrylamide gel electrophoresis. These 
conflicting results are possibly caused by the different methods used. 
Only a few detailed studies have been reported concerning the VLDL 
apoprotein С composition in adult diabetic patients. Pagnan et al10 measured 
a decreased mean relative amount of apoC-III
n
 in normolipidaemic subjects 
with diabetes; no differences in apoprotein С composition were found 
between patients treated with insulin or tolbutamide. Gabor et al3 found in 
patients with diabetes and elevated VLDL levels an increase in the relative 
amount of apoC-III,. In contrast with these data, we found in a larger group 
of patients with Type 2 diabetes and Type IV hyperlipoproteinaemia a 
normal apoC composition of the VLDL fraction. Both apoC-IIIo and apoC-
ІІІ! were not increased in our diabetic group, so the difference with the data 
of Gabor et al can not be explained by the lack of resolution of apoC-IIIn with 
the method used by these authors. The ratio of apoC-II/C-III was also not 
decreased. Increased hepatic VLDL production and/or impaired VLDL 
removal are known to be the basic defects in the mechanism of hypertriglyce-
ridaemia. Alterations in apoprotein С composition of the VLDL particles, 
however, do not seem to play a pathogenetic role. 
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SUMMARY 
Two patients are described with massive hypertriglyceridaemia secondary to 
alcoholic excess in one and uncontrolled diabetes mellitus in the other. After 
alcohol withdrawal and during dietary and insulin treatment there was a 
rapid fall in serum lipids. Postheparin lipoprotein lipase (LPL) activity was 
not decreased in either patient. In the patient with alcoholic lipaemia a low 
apolipoprotein C
n
/C
m
 ratio of the triglyceride (TG)-rich lipoproteins was 
found, which increased by several times during the rapid fall in serum TG. It 
is suggested that inhibition or insufficient activation of LPL due to the low 
apoprotein Сц/Сщ ratio had contributed to the development of the severe 
hypertriglyceridaemia. Furthermore, this patient demonstrated a temporary 
increase in total VLDL-apo E and in the VLDL-cholesterol/VLDL-TG ratio, 
indicating transient accumulation of VLDL remnants. This may be related to 
his relative apo E3 deficiency. 
In the patient with diabetic lipaemia the apoprotein composition was deter­
mined only after normalization of the serum TG. A low apolipoprotein C
u
/ 
C
m
 ratio was repeatedly found. During the development of the diabetes, 
increased synthesis of TG-rich lipoproteins, relatively resistant to the action 
of LPL, may have led to massive hypertriglyceridaemia. 
The pathogenesis of the severe hypertriglyceridaemia and the possible role of 
the alterations in apoprotein composition in these patients are discussed. 
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INTRODUCTION 
Type V hyperlipoproteinaemia is characterized by a markedly increased 
plasma TG concentration, due to an increase in both VLDL and chylomi­
crons in fasting serum. The serum is turbid with a cream layer on top after 
standing at 40C. Clinical features may consist of hepatosplenomegaly, 
eruptive xanthomas, abdominal complaints, pancreatitis and retinal lipaemia. 
Type V HLP can be secondary to a variety of diseases, drugs and dietary 
habits. Poorly controlled diabetes mellitus, alcoholic excess or oestrogens in 
an individual with pre-existing type IV HLP often produce the type V 
pattern.1 In primary type V HLP no underlying cause is found. The removal 
of TG is mediated by LPL;2 this enzyme requires apolipoprotein Сц for its 
activation both in vitro3 and in vivo.4 On the other hand, apo CU[ and several 
other apolipoproteins are known to be inhibitors of LPL in vitro.5·6 We 
studied two patients with severe secondary hypertriglyceridaemia (type V 
HLP) in order to define the possible abnormalities in the apolipoprotein 
composition of the TG-rich lipoproteins and in LPL activity, which may have 
contributed to this disturbance in lipoprotein metabolism. 
PATIENTS 
Patient A, a 42-year old man, was admitted with abdominal complaints, 
headache, weight loss and milky serum. There was a history of alcohol abuse 
for several years (approximately 4 1 beer per day = 160 g alcohol). He 
weighed 72 kg and his height was 187 cm. There were no external signs of 
hyperlipoproteinaemia. The liver was enlarged 4 fingers below the right 
costal margin; the spleen was not enlarged. There were no vascular spiders. 
There were no signs of pancreatitis. The fasting serum lipids were grossly 
increased: TG 82.8 mmol/1 and cholesterol 31.4 mmol/1. Serum bilirubin was 
normal; serum transaminases could not be determined due to turbidity and 
appeared to be normal after normalization of the serum lipids. Gamma-
glutamyl transpeptidase was increased: 1200 U/l at admission (normal up to 
36 U/l). It gradually decreased to 76 U/l in 5 weeks. Alkaline phosphatase 
was only slightly increased (139 U/l) and returned to normal in a few days. 
Plasma sodium and potassium were spuriously low (116 and 3.2 mmol/1, 
respectively), but were normal after normalization of the serum lipids. Renal 
and thyroid function tests were normal. There were no signs of haemolysis. A 
glucose tolerance test performed on the 6th day after admission was comple­
tely normal. X-ray of the upper gastrointestinal tract revealed a duodenal 
ulcer. During the hospital period the serum lipids fell rapidly in response to 
dietary therapy (fat 80 g, carbohydrates 200 g, protein 80 g per day and no 
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alcohol) within two weeks. Two weeks after discharge from hospital the 
serum lipid concentrations were completely normal. During this fall in serum 
lipids we studied the TG and cholesterol concentrations of the lipoprotein 
fractions d<1.0ü6 g/ml (chymolicrons + VLDL), LDL and HDL, the 
apoprotein composition of the TG-rich lipoproteins and LPL and hepatic 
lipase activity in postheparin plasma. 
Patient B, a 37-year old man, was referred with eruptive xanthomas, polyuria 
and polydipsia. He had noticed eruptions on the skin for six months. His 
body weight was said to be unchanged. He did not drink. There were no 
symptoms of cardiovascular disease or pancreatitis. At admission he weighed 
70.0 kg and his height was 1.66 m. Eruptive xanthomas were present on the 
extensor surface of the extremities, buttocks, abdomen, shoulders and neck 
(Fig. 1). The fundi showed retinal lipaemia. The liver and spleen were not 
palpable. The fasting plasma glucose was 18.7 mmol/1. There was glucosuria 
(about 200 g/day), but no ketonuria. Serum lipids were grossly increased: TG 
147 mmol/1, cholesterol 43.2 mmol/1. Plasma sodium was spuriously low (116 
mmol/l), but after normalization of the serum lipids electrolytes were normal. 
Haemoglobin was normal (8.0 mmol/1). Renal and thyroid function tests 
were also normal. 
Upon dietary therapy (sugar-free, 78 g protein, 101 g fat and 194 g carbohy-
drates) the serum lipids fell rapidly. Eruptive xanthomas disappeared within 
two weeks, during which he lost 3 kg weight. From the 11th day on the 
patient received insulin. After 2'Á months, insulin was replaced bij glibencla-
mide. Plasma glucose, lipids and postheparin LPL activity were monitored. 
The method to estimate the apoproteins was not available at the time of 
admission, but was applied afterwards when plasma TG were normal. After 
discontinuation of the oral drug (when the patient's body weight had decrea-
sed to 61 kg) the diabetes was controlled well by diet alone, while plasma TG 
remained below 2.0 mmol/1 during 2 years' follow-up. 
Figure 1. Eruptive xanthomas in patient В with diabetic lipaemia. 
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ANALYTICAL METHODS 
Blood samples were collected after an overnight fast without anticoagulant. 
The lipoprotein fraction d < 1.006 g/ml was isolated from whole serum by 
ultracentrifugation as previously described.7 The HDL fraction was isolated 
after precipitation of the LDL in the d > 1.006 g/ml fraction with heparin/ 
Mn. 2 + · 7 In all fractions cholesterol was determined by an enzymatic method.8 
TG in whole serum and VLDL were determined by a semi-automated 
method.9 
The apo С and apo E contents and subcomposition of the TG-rich lipopro­
teins were determined by analytical isoelectric focusing, using the slightly 
modified method of Weidman et al.1 0 The lipoproteins were washed by 
subsequent ultracentrifugation and delipidated in acetone:ethanol (1:1 v/v) 
according to Warnick et al." The amount of protein loaded onto the gel was 
100-200 μg. After isoelectric focusing the apoproteins were stained with 
Coomassie blue, followed by densitometric scanning on a Shimadzu CS 910 
scanner. No correction was made for higher apo Сц chromogenicity. The 
inter-assay coefficients of variation over a six-month period for determina­
tion of apo Сц/Сщ and apo Ε,/Ετ were 11 per cent and 9 per cent, respectively 
(n = 22). In 27 normolipidaemic subjects, the mean apo Сц/Сщ ratio was 
0.18 ± 0.06 (± SD). 
LPL and hepatic lipase in postheparin serum were determined in patient A 
after intravenous injection of 50 U heparin/kg body weight according to 
Huttunen et al.1 2 (Mean value for LPL in 14 normal men was 8.0 ± 2.5 
μπιοΙ FFA.mr'.h" 1 and for hepatic lipase 25.9 ± 9.2 μπιοί FFA.mr'.h" 1). In 
patient B, LPL activity was determined by the protamine-inhibition 
method.1 3 Mean value for LPL with this method in 22 normal men was 6.3 ± 
2.4 μπιοί FFA.mr'.h" 1 and for hepatic lipase 25.2 ± 6.7 μιηοΐ FFA.mr'.h" 1. 
Results are expressed as mean ± SD. 
RESULTS 
Patient A - The effect of dietary therapy and alcohol withdrawal on plasma 
lipoproteins in patient A is shown in Fig. 2. At admission the cholesterol and 
TG contents in the d < 1.006 fraction were grossly increased and fell rapidly 
to normal levels. On day 5 the serum TG concentration was reduced to 6.2 
mmol/1 and chylomicrons had disappeared completely. The fall of VLDL-
cholesterol was slower than that of VLDL-TG. This is illustrated by the 
course of the ratio of VLDL-cholesterol/VLDL-TG (normal values < 
0.92). On days 5, 8, 12 and 35 this ratio decreased from 2.39 to 1.66, 1.16 and 
0.90, respectively. 
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Figure 2. Plasma lipoprotein concentrations and postheparln LPL activity in patient A 
with alcoholic llpaemla after alcohol withdrawal and dietary therapy. On day 1 chylomi­
crons are Included In the VLDL fraction. 
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Figure 3. Scanning densitometry of apoprotein gels from patient A with alcoholic 
llpaemla on days 1, 5 and В of the hospital period. 
LDL-cholesterol was low at admission (1.82 mmol/1). During the rapid fall in 
plasma TG there was a temporary rise in LDL-cholesterol (Fig. 2). HDL-
cholesterol was extremely low (0.18 mmol/1), but was normalized on day 35 
(1.35 mmol/1). LPL activity in postheparin plasma was not deficient and 
increased on day 5 to 19.6 μιηοΐ FFA.mr'.h" 1 (Fig. 2). Hepatic lipase was also 
within the normal range (18.9-55.7 μπιοί FFA.ml' .h" 1 ). 
The ratio of apoprotein Сц/Сці of the d < 1.006 g/ml fraction was very low 
and increased considerably during the rapid fall in plasma TG (Fig. 3). This 
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ratio continued to increase above the normal level after chylomicrons had 
disappeared. On day 1 the apo €„/€,„ ratio was 0.07 (0.15 on day 5 and 0.37 
on day 8). 
The patient showed relative deficiency of apo ET as determined by the ratio 
of apo Ε,/Ετ. The apo Ε,/Ετ ratio was always < 1.10 and > 0.20, indicating 
a heterozygous apo E·, phenotype.14 The relative concentration of total apo E 
was increased temporarily. On day 1 the amount of total apo E in the VLDL 
+ chylomicrons fraction was 34 per cent and on days 5, 8 and 12 the amount 
of total apo E in the VLDL fraction was 47, 37 and 27 per cent (expressed as 
per cent of protein loaded onto the gel; Fig. 3). 
In summary, this patient with severe hypertriglyceridaemia showed a rapid 
fall in plasma TG, during which a temporary rise in VLDL-cholesterol/ 
VLDL-TG ratio and in the relative amount of total apo E was seen. There 
was a marked rise in the apo C
u
/C
m
 ratio of the TG-rich lipoproteins. LPL 
and hepatic lipase in postheparin serum were not deficient. 
Patient В - The effect of treatment in patient В with "xanthoma diabetico­
rum" is shown in Fig. 4. Plasma TG was grossly increased up to 147 mmol/1. 
Most of the fall in plasma TG occurred as a result of dietary therapy alone (to 
41.1 mmol/1) and a further decrease was seen after institution of insulin 
treatment. Afterwards it appeared that this patient was not insulin-depen-
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Figure 4. Plasma lipids, glucose and postheparin LPL activity In patient В with diabetic 
llpaemia during treatment as Indicated. 
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dent, and this further decrease in plasma TG might therefore have occurred 
without insulin. Fasting plasma glucose decreased to 12.Ü mmol/1 upon diet 
alone and to 6-8 mmol/1 upon insulin treatment, while glucosuria disappea-
red. Postheparin LPL activity was in the high normal range in the first week 
when plasma TG concentrations were very high. Hepatic lipase was also 
normal (15.7-23.8 μπιοΙ FFA.ml-'.h"1). 
The apoprotein composition of the VLDL fraction was determined later on 
several occasions after normalization of the plasma TG. The apo Сц/Сщ ratio 
was decreased: 0.08 ± 0.04 (n = 4). The apo Ε,/Ετ ratios were normal (> 
1.10). 
DISCUSSION 
Hypertriglyceridaemia can result from either increased TG secretion into the 
blood or impaired TG removal, or from a combination of both. In type V 
HLP secondary to alcohol and diabetes, overproduction of VLDL has been 
demonstrated.15 The increased VLDL production may lead to saturation of 
the removal mechanism which is shared by VLDL and chylomicrons16 and 
thus cause fasting hyperchylomicronaemia (the type V pattern). The key 
enzyme in the catabolism of plasma TG is LPL.2 Subnormal postheparin 
lipolytic activity has been reported in alcoholic lipaemia17 and diabetic 
lipaemia.18 In healthy male volunteers a transient increase in plasma TG 
during ethanol intake has been seen, followed by reduction to normal and an 
increase in LPL activity in adipose tissue biopsy specimens.19 Apparently, 
ethanol increases hepatic secretion of VLDL; it is therefore only in suscepti­
ble individuals with abnormal or limited adaptive increase in TG removal 
that the type V pattern is induced. The diabetic patients with type V HLP 
reported by Bagdade et al were insulin-dependent, unlike our patient with 
"xanthoma diabeticorum", and insulin treatment resulted in a prompt return 
of the increased plasma TG and decreased lipolytic activity to normal.1 8 
However, our patients with type V HLP secondary to alcohol and diabetes 
had normal postheparin LPL values. It therefore seems that impaired TG 
removal cannot be ascribed to deficiency of LPL in our patients. 
LPL activity is modulated by apoprotein С on the surface of chylomicrons, 
VLDL and HDL. Apo Сц is a specific activator of LPL,3 whereas several 
other apoproteins, including apo Сщ, inhibit LPL in vitro.5,6 The important 
role of apo Сц in vivo has been demonstrated in a patient with massive 
hypertriglyceridaemia who lacked this apoprotein.4 Since the effects of apo 
Qi and apo C
ni on LPL are opposite, their relative proportions on the surface 
of the TG-rich lipoproteins have been suggested to influence the rate of TG 
removal from the plasma.20,21 It should be emphasized, however, that in 
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human subjects the role of apo Сщ in vivo is still uncertain at present. 
The markedly reduced apo Сц/Сщ ratio in our patient with alcoholic lipaemia 
may have limited the clearance of TG-rich lipoproteins by insufficient 
activation or inhibition of LPL. The enhanced hepatic secretion of lipopro­
teins of such composition in response to alcohol abuse then resulted in severe 
hypertriglyceridaemia. After alcohol withdrawal the apo СЦ/СЩ ratio rose. 
Alcohol withdrawal probably led to decreased hepatic secretion of lipopro­
tein particles; these particles had a relatively higher apo Сц content, which 
may have promoted TG removal. One can only speculate as to how these 
changes in the С apoproteins in response to alcohol were induced. In patients 
with more severe liver disease, a decrease in the activity of the enzyme 
lecithin-cholesterol acyltransferase has been described, associated with alte­
rations in lipoprotein composition, probably due in part to decreased choles­
terol esterfication.22 The altered surface composition of the TG-rich lipopro­
teins could have caused temporary differences in the binding properties of 
the С apolipoproteins in our patient, although his liver function was not 
severely impaired. Furthermore, HDL serves as a reservoir for apo C,2 1 and 
less apo С seems to have been available for in-vivo transfer from HDL to 
newly secreted TG-rich lipoproteins due to the extremely low HDL concen­
tration. The rise in apo Сц/Сщ ratio does not seem to be a consequence of 
disappearance of chylomicrons or fall in plasma TG itself, since larger 
lipoprotein particles have the same or even a higher apo Сц/Сщ ratio than 
smaller ones2 4 and no preferential removal of apo Сц or apo C
m
. | has been 
documented, at least during lipolysis of VLDL from normal subjects in 
vitro.25 
In patient B, treatment resulted in a rapid fall in plasma TG concentration. 
The apoprotein pattern of the TG-rich lipoproteins was not determined at 
the time of massive hypertriglyceridaemia, but the apo Сц/С,,, ratios ob­
tained afterwards at a normal plasma TG concentration were reduced. Appa­
rently, lipoproteins of such composition are relatively resistant to the action 
of LPL; this may have induced the type V pattern during the development of 
the diabetes with increased secretion of VLDL particles.1'1 Obviously, during 
good diabetic control the clearance of (smaller numbers of) VLDL particles 
is normal in spite of the decreased apo Сц/Сщ ratio in this patient. The cause 
of the decreased ratio of apo C
u
/C
m
 in this patient is not clear; he could be 
heterozygous for the rare autosomal recessive disorder apolipoprotein C,, 
deficiency.2627 Obviously, the relative deficiency of apo Сц alone does not 
lead to hypertriglyceridaemia in this patient. This is in agreement with 
reports on inherited relative apo Сц deficiency26 2 7 and with in-vitro28 and in-
vivo4 2 9 studies showing that the amount of apo Сц is not rate-limiting for 
maximal hydrolysis of triglycerides. 
Total apo E, deficiency is probably the limiting factor in the uptake and 
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degradation of VLDL remnants by the liver, for it has been suggested that 
apo ET is the major determinant of the hepatic recognition of the lipoprotein 
remnants 1() In combination with other factors (e g overweight, alcoholic 
excess, diabetes) type III HLP can emerge, characterized by accumulation of 
VLDL remnants. VLDL remnants are relatively neh in cholesterol and total 
apo E1 1 and are probably the intermediate product in the conversion of 
VLDL to LDL 3 2 Apo E^ deficiency is inherited in a recessive mode. 1 0 1 4 
Patient A had a heterozygous apo E, phenotype (relative deficiency of apo 
Ε
λ
) During the rapid fall of serum lipids there was a temporary rise of the 
VLDL-cholesterol/VLDL-TG ratio and an increased amount of total VLDL-
apo E, indicating accumulation of VLDL remnants in this patient The same 
mechanism as in type III HLP may have been temporarily present during the 
fall in serum TG and increased production of VLDL remnants. The increase 
in LDL-cholesterol can be explained by a temporarily increased (although 
delayed) conversion of VLDL remnants to LDL (Fig 2) The extremely low 
HDL-cholesterol concentration at admission can be explained by impaired 
clearance of the TG-rich lipoproteins, since HDL is partly derived from the 
surface components of these lipoproteins 2 3 Enhanced catabohsm of these 
lipoproteins resulted in the increase of HDL-cholesterol (Fig 2) 
In conclusion, patient A demonstrated a transient abnormally low ratio of 
apo Сц/Сц] of the TG-rich lipoproteins, which may have contributed to the 
severe hypertnglycendaemia by limited clearance of these lipoproteins by 
LPL. This ratio increased by several times during the rapid fall in plasma TG. 
LPL was not deficient The relative apo E^ deficiency may have caused the 
temporary accumulation of VLDL remnants in this patient Patient В had 
permanent low ratios of apo C
n
/C
m
 of the VLDL fraction determined at 
normal plasma TG concentrations During the development of diabetes in 
this patient, increased synthesis of TG-rich lipoproteins with low apo Сц/Сщ 
ratio, relatively resistant to LPL, may have caused the massive hypertnglyce­
ndaemia An altered apoprotein С composition may therefore have been of 
importance in the development of the massive hypertnglycendaemia, in 
combination with VLDL overproduction by the liver. Determination of 
apoproteins provides more insight into the pathogenesis of hyperhpoprotein-
aemias, although much remains to be clarified about the metabolism of these 
apoproteins 
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SUMMARY 
The underlying pathophysiological defect was studied in four siblings with 
familial hyperchylomicronemia. Deficiency of apolipoprotein C-II and E-3 
was identified. In addition, these subjects had markedly decreased LPL 
activity in postheparin plasma. Addition of normal plasma to the assay as 
source for apoC-II enhanced LPL activity only to a limited extent. In contrast 
with previously reported patients with apoC-II deficiency, a far less pronoun-
ced effect of intravenous infusion of normal plasma was seen in one of the 
siblings, probably due to the combined deficiency of apoC-II and LPL. 
Plasma VLDL-TG turnover rate was not decreased in one of the siblings with 
apoC-II and LPL deficiency, suggesting different metabolic pathways for 
chylomicrons and VLDL. Family study confirmed an autosomal recessive 
mode of inheritance both for apoC-II and for apoE-3 deficiency. The mode 
of inheritance for LPL deficiency could not be established exactly. 
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INTRODUCTION 
Familial hyperchylomicronemia (type I hyperlipoproteinemia) is caused by 
deficiency of lipoprotein lipase (LPL), leading to severe impairment of the 
clearance of chylomicrons-TG from the plasma.12 For the activation of LPL 
the presence of apoC-II is required both in vitroJ 4 and in vivo. Transfusion 
with blood or plasma in a patient with massive hypertriglyceridemia who was 
lacking this apoprotein resulted in a dramatic and prolonged fall in plasma 
TG, probably by supplying the missing activating factor.5 In this case, family 
study revealed that the defect was inherited as an autosomal recessive trait.6 
It was suggested to call this new disease "apolipoprotein C-II deficiency" to 
differentiate it from "lipoprotein lipase deficiency". Since then only a few 
additional cases have been reported.7'8·9 We reinvestigated a family previ-
ously described by Lamberts et al10 with the clinical and biochemical features 
of type I HLP. A combination of both apoC-II deficiency and LPL deficiency 
was identified in this family. 
MATERIALS AND METHODS 
The clinical data of the four siblings, HV, AV, BV and PV with hyperchylo-
micronemia were previously described in detail.10 They had milky serum, 
hepatosplenomegaly, lipemia retinalis and abdominal complaints since their 
first decade. Causes for secondary HLP in these patients could be excluded. 
Consanguinity was not known in this family. Hemipancreatectomy and 
splenectomy were performed in BV when he was 26-yr-old because of 
hemorrhagic pancreatitis. Glucose tolerance was normal in all four. On a low 
fat diet the patients had no complaints. During the year before this study the 
fasting plasma TG on this diet varied from 4-15 mmol/1 in HV, 3-4 mmol/1 in 
AV and 5-20 mmol/1 in BV. PV was investigated only once. Inherited 
thyroxine binding globulin deficiency had also been found in HV and BV, but 
not in AV.10 
Fasting blood was obtained from these four siblings for the determination of 
1) TG and cholesterol in whole plasma and in the fractions d < 1.006 g/ml 
(containing VLDL and chylomicrons), LDL and HDL; 2) apoprotein compo-
sition of fraction d < 1.006 g/ml; 3) presence of apoC-II in whole and 
delipidated plasma by double immunodiffusion with specific anti-apoC-II 
antiserum; 4) LPL and hepatic lipase in postheparin plasma, and 5) LPL 
activating ability of the patients plasma in an assay with guinea pig posthepa-
rin plasma. 
AV was studied more thoroughly during hospitalization: VLDL-TG turnover 
rate was measured; the effect of infusion of plasma on plasma lipids, LPL 
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activity and LPL activating ability was determined; the TG and cholesterol 
concentrations and apoprotein compositions of the VLDL and chylomicrons 
were measured separately. She had been asked to use as much fat as she 
could tolerate 1 week prior to admission. During this week she consumed 
22% of calories from fat, 12% from protein and 66% from carbohydrates. In 
the hospital she consumed an isocaloric diet containing 40% of calories from 
fat. After discharge from the hospital the amount of fat had to be reduced 
again to about 22% because of abdominal complaints. 
In addition to the four affected siblings, 14 members of the family were 
investigated in order to establish the mode of inheritance and possible 
interrelationship of apoC-II, apoE-3 and LPL deficiency. From these sub­
jects (parents, 5 siblings and 7 children) blood was examined after an 
overnight fast. Informed consent was obtained from all subjects. 
Analytical Methods 
Blood samples after an overnight fast were collected into EDTA (1 mg/ml) 
and chilled to 4°C. Plasma was separated after low speed centrifugation at 
4°C. Chylomicrons were separated in an IEC B60 ultracentrifuge (Damon/ 
IEC, Needham Heights, Mass., USA): two ml of plasma were overlayered 
with 4 ml of d = 1.006 g/ml density solution and centrifuged at 14,000 rpm 
(26,000 x g) during 30 min in the SW41 rotor at 10oC. The chylomicrons 
were isolated by aspiration of the first half ml. VLDL were isolated from 
whole plasma and from the chylomicron-free bottom fraction by ultracentri-
fugation as described previously." The HDL fraction was isolated after 
precipitation of LDL in the d > 1.006 g/ml fraction with heparin/Mn2"1"." In 
all fractions, cholesterol was determined with an enzymatic method.1 2 TG in 
whole plasma, in the VLDL- and in the chylomicron fraction were determi­
ned with a semi-automated colorimetrie method. n 
The ratios of apoC-II/C-III and apo E-3/E-2 in chylomicrons, VLDL and 
VLDL + chylomicrons were determined with analytical isoelectric focusing. 
The method of Weidman et al (slightly modified) was used.14 The lipopro­
teins were washed by a subsequent ultracentrifugation and delipidated in 
acetone:ethanol (1:1 v/v) according to Warnick et al.15 The delipidated 
apoproteins were dissolved in 0.2 M Tris-HCl buffer in 8 M urea, pH 8.2, 
containing 0.1% (w/v) dithiotreitol. The amount of protein measured with 
the Lowry method1 6 loaded on the gel was 100-200 μg. After IEF the 
apoproteins were stained followed by densitometric scanning on a Shimadzu 
CS 910 scanner within 3 days. The inter-assay precision was determined using 
VLDL isolated from pooled serum. VLDL were divided in small aliquots and 
extracted separately; apoproteins were stored at -20oC prior to analysis. The 
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inter-assay coefficients of variation over a half-year time period for the 
determination of apoC-II/C-III and apoE-3/E-2 were 11% and 9% respecti­
vely (n = 22). No correction was made for higher apoC-II chromogenicity. 
Isolation of apoC-II and preparation of specific antiserum was performed as 
follows: VLDL obtained from fresh serum was rewashed by ultracentrifuga-
tion and delipidated with acetone-ethanol.15 Apoproteins were dissolved in 
0.01 M Tris-HCl buffer in 6 M urea pH 7.5. ApoC was isolated using 
Sephacryl S 200 column chromatography and was further fractionated with 
DEAE cellulose chromatography using the same buffer and a linear gradient 
from 0.0-0.2 M NaCI. The apoC-II isolated in this manner was not homoge­
neous as appeared by analytical IEF. It was purified by preparative flat bed 
IEF according to the method of Marcel et al.17 Specific antiserum against 
apoC-II was raised in rabbits. Using the Ouchterlony technique this antise­
rum showed a precipitation arc with apoC-II and did not react with other 
pure human apoproteins (C-IIIj, C-IIb, A-I, A-II and E) or with human 
albumin. With this monospecific antiserum the presence of apoC-II was 
tested in plasma whether or not delipidated. The plasma was delipidated 
according to Cham and Knowles18 with butanol:di-isopropylether 30:70 (v/v) 
during 1 hr. 
Lipoprotein lipase and hepatic lipase in postheparin plasma were measured 
with the immunochemical technique as described by Huttunen et al19 15 min 
after injection of 50 U heparin per kg bodyweight (in subject AV also after 
injection of 100 U heparin per kg). Lipoprotein lipase is selectively measured 
after inactivation of hepatic lipase by specific antiserum at low salt concentra­
tion in the presence of serum activator. In the assay of hepatic lipase the 
activity of LPL is inhibited by raising the NaCI concentration to 1.0 M and 
omitting the serum activator. The specific antiserum to hepatic lipase was 
raised in rabbits after partial purification of hepatic lipase by heparin-
sepharose chromatography with linear NaCI gradient from 0 to 1.5 M NaCI. 
The lipolytic activity of the eluate at 0.55 M NaCI was resistant to 1 M NaCI 
and not activated by serum. The antiserum caused 63% inhibition of total 0.1 
M NaCI lipolytic activity. An inhibition of 98%-99% was obtained of the 1 M 
NaCI lipolytic activity in four different samples with a wide range in hepatic 
lipase activities after incubation of 50 μΐ of postheparin plasma with an equal 
volume of antiserum. Testing 10 μΙ postheparin plasma at 0.1 M NaCI a linear 
free fatty acid release was found during one hour, using triolein emulsified 
with gum arabic as substrate. The LPL assays were carried out in triplicate 
and were reproducible within 5%. Normal human pooled plasma was added 
in the LPL assay as source of apoC-II to attain full activity. In our assay 
system maximal activity was achieved after addition of 25 μΐ of normal 
plasma. In the LPL assay of the patients both normal plasma and their own 
preheparin plasma were used as activator. The coefficient of variation of one 
H I 
control plasma sample (η = 13) was 7.2% for LPL and 5.0% for hepatic 
lipase. The values were corrected for the day to day variation in a standard 
postheparin plasma sample. 
The ability of human plasma to activate LPL was measured with use of 
guinea pig postheparin plasma and 10% Intralipid® (Kabivitrum BV, 
Amsterdam) as substrate according to Chu et al.2 0 A micromethod was used 
and the increase of FFA was determined colorimetrically with application of 
the method of Noma et al.21 Fifty μΐ of test plasma was used in the assay. 
Increasing amounts of guinea pig postheparin plasma (0-200 μΐ) added to the 
assay medium caused a linear increase in FFA production. The conditions of 
the assay were such that during the incubation time of 60 min there was a 
linear increase in lipolytic activity with increasing amount of human normal 
and lipemic plasma up to 120 μΐ. Results are expressed as μπιοί FFA released 
per ml of human plasma per hour after substraction of the basal lipolytic 
activity of guinea pig postheparin plasma. The interassay precision of the 
method was 7.1% (n = 7). This method is based on the observation that 
guinea pig plasma does not appear to contain activator peptides for LPL. 2 2 , 2 3 
However, VLDL of guinea pig plasma does stimulate bovine milk LPL, 
whereas the infranatant causes inhibition. In total plasma these adverse 
effects neutralize each other.24 Thus, the method of Chu et al can still be used to 
estimate the extra amount of activating peptides present in human plasma. 
The turnover rate of VLDL-TG was assessed according to Farquhar et al25 
and Nikkilä and Kekki.26 After an overnight fast 100 μ Ο 2-3H-glycerol (the 
Radiochemical Centre, Amersham, England) was administered intrave­
nously as a pulse injection. VLDL-TG radioactivity and concentration were 
determined in nine blood samples until 7 hours after administration. TG 
were extracted according to Royer and Ко. 2 7 The FCR was obtained from 
the descending slope of the VLDL-TG radioactivity curve. Only monoexpo-
nential curves were accepted and a steady-state in VLDL-TG was required 
(variation in TG < 10%). The validity of the 2-3H-glycerol technique for 
estimating VLDL-TG turnover during a relatively short period has been 
questioned. Zech et al28 found by extending the observation to 48 hr, that 
after 12-18 hr the fall in specific activity of VLDL-TG was not mono-
exponential; a slow tail emerged, ascribed to a more slowly turning-over 
precursor compartment. So, our results of VLDL turnover may be overesti­
mated by neglecting this slow component, although studies have been 
reported in which by this method similar results were obtained compared to 
other methods as the lipolytic rate procedure2 9 and the VLDL-apoB turn­io 
over. 
For statistical analysis Student's t-test for unpaired data and Pearson's 
correlation coefficient were used. Results are expressed as mean ± SD. 
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RESULTS 
Plasma Lipids, Lipoproteins and Apoproteins 
During a moderately fat-restricted diet the fasting serum of the siblings HV, 
AV, BV and PV showed a thick sticky cream layer on top after standing at 
40C. The infranatant was clear in HV, AV and PV and remained opalescent 
in BV. The quantitative lipoprotein data are summarized in Table 1. More 
than 60% of the plasma TG was in the chylomicrons fraction. The concentra­
tions of LDL-cholesterol and of HDL-cholesterol were markedly reduced. 
The apoprotein pattern of the VLDL + chylomicrons fraction of three of 
the siblings are shown in Fig. 1. Apoprotein C-II was visually absent in all 
four subjects and could not be detected after scanning densitometry in the 
fractions chylomicrons, VLDL and VLDL + chylomicrons. Furthermore, 
the apoE-3 band was absent in all four patients. The same apoprotein pattern 
was obtained on different occasions. Blood sampled from AV after using a 
diet with a normal fat content showed also a total lack of apoC-II and apoE-
3. ApoC-II could not be detected with double immunodiffusion in all four 
subjects both in whole plasma and in delipidated plasma (Fig. 2). 
Table 1. Plasma lipoprotein lipid concentrations In the four siblings with familial hyper-
chylomlcronemla during a moderately fat-restricted diet after an overnight fast. 
Subject 
HV 
AV 
BV 
PV 
Sex 
M 
F 
M 
M 
Age 
Yrs 
36 
34 
33 
31 
"i Ideal 
Bodvweight 
117 
102 
88 
116 
Triglycerides (ιπιποΙ/Ι) 
Total 
3 90 
3 02 
11 80 
5 76 
d < 1 006 
Fraction 
2 93 
2 49 
10 89 
4 45 
Total 
2 25 
1 80 
4 43 
2 45 
Cholesterol (mmol/l) 
d < 1 006 
Fraction 
0 93 
0 79 
3 01 
1 24 
LDL 
0 92 
0 58 
1 08 
0 79 
HDL 
0 4 0 
0 43 
0 34 
0 42 
Postheparin Lipolytic Activity 
LPL activity in postheparin plasma was very low in the four siblings, when 
the measurement was performed with 25 μΐ of the patients own preheparin 
plasma as LPL activator. The activity was only slightly enhanced by substitu­
tion of the patients own plasma by normal plasma as a source for apoC-II. No 
activation could be detected after increasing the amount of the patients own 
preheparin plasma to 100 μΙ. Hepatic triglyceride lipase activity was also 
reduced (Table 2). 
In patient AV, LPL activity was also measured during a period of 2 weeks in 
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Figure 1. Isoelectric focusing gels of urea soluble apoproteins of VLDL. A: type III HLP 
(apoE-3 deficiency). B: normal (apoE-4 band present). C: normal. AV, BV and HV: 
siblings with apoC-li and E-3 deficiency. 
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1 
О 
6 
Figure 2. Ouchterlony double Immunodiffusion with anti-human apoC-ll (center well) 
against dellpldated plasma of the four affected siblings (3-6) and a hypertriglycerldemic 
(1) and a normolipidemic subject (2). 
which she had used a normal amount of fat. LPL activity remained low while 
the plasma TG increased gradually. On four different occasions LPL ranged 
from 1.3-3.8 цтоі FFA.mL'.h' 1, adding normal plasma and ranged from 
1.3-2.5 μιτιοί FFA.mr'.h" 1 adding own plasma as LPL activator. Hepatic 
lipase varied between 7.3 and 10.4 μιτιοί FFA.mr' .h - 1 . 
The possible presence of an inhibitor of LPL or hepatic lipase in the plasma 
Table 2. Lipoprotein lipase and hepatic lipase in postheparln serum (50 U/kg) In the 
siblings with apoprotein C-ll deficiency compared to normal subjects. The activities were 
determined with patients own preheparin plasma and with normal plasma (25 ul) as 
source for apoC-ll. 
HV 
AV 
AV* 
BV 
PV 
A 
0.2 
1.2 
0.8 
1.9 
0.8 
Lipoprotein Lip; 
μιτιοί 
Normal males (n = 14) 
Normal females (n = 15) 
FFA · ml ' 
В 
0.4 
1.2 
1.1 
0.8 
1,1 
ise 
h 
С 
1.1 
2.0 
1.9 
3.2 
1.8 
8.0 ± 2.5 
8.9 ± 2.2 
Hepatic Lipase 
цтоі FFA ml ' • h ' 
5.5 
5.6 
9.0 
12.5 
8.3 
25.9 ± 9.1 
16.2 ± 6.4 
(A) no plasma activator (B) addition of 25 ul of own plasma, and (C) of normal plasma in the assay 
* Activities measured after injection of a heparin dose of 100 U/kg bodyweight 
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of the patients was studied by mixing postheparin plasma obtained from 2 
affected patients with equal amounts of postheparin plasma from two normal 
subjects. Of these four different mixtures the activities of LPL and hepatic 
lipase were analyzed. The LPL activities in the mixtures were 96.9 ± 5.0% 
(n=4) of the expected values based on the LPL determination in the single 
postheparin sera. The activities of hepatic lipase in the mixtures were 100.9 ± 
2.1% of the expected values. 
LPL Activating Ability 
With the use of guinea pig postheparin plasma very low values for LPL 
activating ability were found in the siblings with apoC-II deficiency (Table 3). 
Increasing amounts of the patients plasma added to the assay system (75-200 
μΐ) did not increase FFA release, whereas a linear increase was seen by 
addition of normal sera up to 120 μΐ. 
In agreement with Chu et al20 LPL activating ability was significantly 
increased in a group of hypertriglyceridemic subjects (p<0.001, Table 3). A 
significant positive correlation between LPL activating ability and plasma TG 
concentration (r=0.80, p<0.001, n=50) was found. In patient AV LPL 
activating ability remained low also during a normal-fat diet, despite a 
gradual rise in plasma TG. 
The possible presence of inhibitors in the plasma of the siblings was also 
investigated. Equal amounts of plasma of the patients and of normal plasma 
were mixed. The LPL activating abilities of these mixtures were 101 ± 9% 
of the sum of the individual values for the single sera. 
Table 3. Ability of activating guinea pig lipoprotein lipase and plasma TG concentration 
of normal controls, patients with hypertriglyceridemia and the siblings with apoprotein 
C-ll deficiency. 
Subjects 
Normal subjects 
Hypertiglyceridemia 
HV 
AV 
BV 
PV 
Number 
30 
20 
TG 
(mmol/1) 
1.06 ± 0.36 
4.01 ± 2.23 
3.90 
3.02 
11.80 
5.76 
LPL Activation 
(цтоі FFA · 
ml ' h - ' ) 
20.0 ± 4.4 
31.5 ± 7.1 
1.7 
0.9 
2.1 
1.0 
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Infusion of Plasma 
The effect of intravenous infusion of two units of fresh normal plasma (500 
ml in 90 min) was studied in patient AV while she consumed a diet containing 
40% of calories from fat (Fig. 3). The gradual rise in plasma TG was abruptly 
interrupted for two days after the infusion of plasma. Plasma TG concentra­
tion fell from 6.32 mmol/1 to 3.84 mmol/1 2 hr after the end of the plasma 
infusion and was 4.72 mmol/1 after 24 hr. The fall in plasma TG was not due 
to the duration of fasting (until noon) since on other occasions plasma TG 
remained constant during that time. At 48 hr after the infusion the plasma 
TG concentration was increased considerably and continued to rise until the 
amount of fat in the diet had to be reduced because of abdominal complaints. 
The changes in plasma TG reflected mainly the changes in chylomicrons-TG, 
whereas the VLDL-TG concentration remained constant. However, the 
VLDL-cholesterol concentration increased from 0.86 mmol/1 to 1.64 mmol/1 
after 24 hr and to 1.78 mmol/1 after 48 hr followed by a gradual decrease to 
1.15 mmol/1. There was a temporary rise in the VLDL-cholesterol/VLDL-
TG ratio from 0.52 to a maximum of 0.74 after 48 hr. The LDL- and HDL-
± 20 % 
ДО % fat 
± 2 0 % fat 
12.0-1 
10.0-
? 8.0 4 
E 
S 6.0 Ч 
Ό 
plasma 
4) 
υ 
> £ 4.0-
2 . 0 -
Αρο CnJ 
total 
• plasma TG 
г24.0 ν 
-20.0 С 
І 
iL 
h 16.0 ô E 
И 2 . 0 ; 
'с 
h θ.ο о, 
h А.О ·| 
Figure 3. Effect of Infusion of two units of plasma on plasma TG, chylomlcrons-TG and 
LPL activating ability during a diet containing 40% of calories from fat. The presence of 
apoC-ll by IEF Is Indicated by + or -. 
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cholesterol concentrations were not influenced by the infusion of plasma. 
The apoprotein patterns in the VLDL fraction and in the VLDL + 
chylomicrons fraction were daily monitored. A small band at the apoprotein 
C-II position could be detected for 48 hr. This band was maximally present in 
the chylomicrons + VLDL fraction. A band at the apoE-3 position was 
detected for 24 hr, maximally present in the VLDL fraction. Examination of 
the plasma of the two donors revealed normal apoprotein C-II patterns 
(apoC-II/C-III ratios 0.23 and 0.29) but an intermediate amount of apoE-3 in 
one donor and a normal amount in the other (apoE-3/E-2 ratios 1.14 and 
1.86). A small increase in LPL activating ability to maximally 3.0 цгтюі 
FFA.mr'.h"' was noticed after the infusion of plasma. This increase was 
present during the same time that the apoprotein C-II band could be detected 
(Fig. 3). 
The LPL activity was still very low the day after the infusion of plasma: 2.5 
μπιοί FFA.mr'.h" 1 using patients own plasma as activator and 2.7 цтоі 
FFA.mr'.h" 1 with normal plasma as activator. 
VLDL-TG Turnover Rate 
VLDL-TG turnover rate was measured in AV during a diet containing 
approximately 20% of calories from fat. The plasma TG concentration in the 
week before, on the day of measurement and the day after the experiment 
was in a steady state (3.16-3.86 mmol/1). VLDL-TG concentration measured 
after removal of the chylomicrons was 1.53 mmol/1 (slightly elevated); the 
FCR was 0.20 h"1, lower than in 6 normal persons (Table 4). However, the 
mean FCR found in type IV subjects was considerably lower (0.09 h"1). The 
Table 4. VLDL-TG concentration, fractional catabollc rate (FCR) and VLDL-TG turnover 
rate In subject AV with apo CH deficiency during a moderately fat-restricted diet In 
comparison with normal controls and patients with type IV-HLP (results are means and 
ranges). 
VLDL-TG 
Turnover Rate 
VLDL-TG FCR (цтоі · 
(mmol/1) (h ') kg · ' · h ') 
Subject AV 
Normal subjects 
(n = 6) 
Type IV HLP 
(n = 6) 
1.53 
0.55 
(0.28-0.83) 
3.46 
(1.82-7.00) 
0.20 
0.39 
(0.27-0.60) 
0.09 
(0.05-0.18) 
13.0 
7.2 
(4.3-9.4) 
10.8 
(5.4-22.1) 
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VLDL-TG turnover rate in AV was higher (13 0 μιτιοί kg ' h ') than in the 
normal subjects 
Results of the Family Study 
TG was measured in whole plasma and the VLDL fraction and cholesterol 
was measured in whole plasma and the VLDL, LDL and HDL fractions The 
plasma lipid values were in the normal range in all subjects, except for high 
HDL-cholesterol levels in some subjects (Table 5) 
The apoC-II/C-III ratio of the VLDL fraction was significantly lower in 10 
relatives compared to 27 normal subjects (0 09 ± 0 03 vs 0 18 ± 0 06, 
III 
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è-r® ί-ϊ-π à-^ s à i i ¿ ά ò 
1 2 3 4 5 6 7 8 9 
1 1 О normal 
Ш (З heterozygous for аро Сц deficiency 
Η 9 homozygous for аро Сц deficiency 
S ® not analyzed 
Figure 4. Pedigree of the family showing the results of relatives tested for apoC-ll 
deficiency. Propositi were subjects II,, II}, II, and ІЦ. 
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Figure 5. Pedigree of the family showing the distribution of apoE phenotypes. Propositi 
were subjects II,, ll2, Из and ІЦ. 
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p<0.001). In 4 relatives with a very low VLDL-protein concentration no 
accurate estimation of the apoC proteins could be obtained. 
The LPL activating ability was also significantly lower in the relatives ( n = l l ) 
compared to 30 normal subjects (13.2 ± 4.4 vs 20.0 ± 4.4 цтоі FFA.mr'.h" 1, 
ρ < 0.001). An overlap in the apoC-II/C-III ratio was noticed for normals 
and obligate heterozygotes for apoC-II deficiency. In accordance with Cox et 
al6 combination of apoC-II/C-III ratio with the LPL activation assay can help 
to identify heterozygotes for apoC-II deficiency, since both values were 
significantly reduced in our family and in obligate heterozygotes.6·47 Relatives 
who had 50% or less of the normal value for the apoC-II/C-III ratio or for 
LPL activating ability were considered to be heterozygote for apoC-II 
deficiency (Fig. 4). 
Identification of the apoE-3 phenotype was based on the relative concentra­
tion of apoE-3 as determined by the apoE-3/E-2 ratio. As cutoff limits to 
distinguish normal subjects (apoE-N phenotype), heterozygotes (apo E-ND 
phenotype) and homozygotes (apo Ε-D phenotype) for apoE-3 deficiency, 
were used, respectively, apoE-3/E-2 ratios of >1.10, 0.2 to 1.10 and <0.20 
Table 5. HDL-cholesterol (HDL-chol), postheparln lipoprotein lipase (LPL), hepatic 
lipase (HL), LPL activating ability and apoC-II/C-III ratio In relatives of subjects with 
apoC-II deficiency. 
LPL apo 
Pedigree HDL-chol LPL HL Activation C-II/C-III 
position (mmol/l) (mol FFA • ml"1 · h ') ratio 
M 
h 
Us 
Пб 
Ib 
π« 
ІІ 9 
III, 
IIb 
Шз 
ІІІ4 
ш, 
ІНб 
Hb 
2.13 
1.63 
2.02 
2.08 
1.40 
1.50 
1.42 
1.33 
1.43 
1.50 
1.78 
1.69 
1.52 
1.63 
A* 
6.8 
7.7 
6.4 
-
6.1 
13.8 
3.7 
12.4 
-
-
-
-
-
-
В** 
9.4 
10.1 
8.7 
-
5.5 
14.4 
6.2 
12.6 
-
7.0 
9.8 
-
-
-
18.5 
15.9 
9.7 
-
7.9 
20.2 
13.0 
22.7 
-
19.6 
31.4 
-
-
-
17.5 
9.8 
12.6 
9.2 
21.2 
14.5 
19.2 
6.8 
10.9 
-
-
-
11.3 
12.4 
0.06 
— 
0.04 
0.06 
0.15 
0.09 
0.10 
0.10 
0.10 
-
-
— 
0.06 
0.09 
* A addition of own plasma, ** В of normal plasma as activator In the assay 
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according to Weidman et al.1 The inheritance pattern for apoE-3 deficiency 
is shown in Fig. 5. 
LPL and hepatic lipase activities in postheparin plasma, measured with 25 μΐ 
of normal plasma as activator in 9 relatives were all in the normal range 
(Table 5). It was not possible to distinguish heterozygotes for LPL deficiency 
from normal subjects. 
DISCUSSION 
Deficiency of postheparin LPL activity was first recognized as the underlying 
defect in type I HLP by Havel and Gordon.1 Until recently several studies 
concerning type I HLP revealed that decreased LPL activity in vitro did not 
result from a lack of activating factor nor from the presence of inhibitors of 
LPL in the serum of the affected subjects.1,31·32·33 However, Brunzell et al 
found in the plasma of two patients with type I HLP and apparently low LPL 
activity inhibitors of normal adipose tissue LPL.9 The first patient with severe 
hypertriglyceridemia due to a deficiency of the activating factor of LPL, 
apoC-II, was described by Breckenridge et al.5 Since then only a few other 
patients with apoC-II deficiency have been detected.7 8 - 9 Thus, type I HLP 
can be caused by several mechanisms. 
We now report another family with hyperchylomicronemia due to apoC-II 
deficiency. In our propositi apoC-II was absent as assayed by immunodiffu­
sion and IEF. ApoC-II deficiency was also confirmed by the assay of LPL 
activating ability of the plasma of the four propositi, testing the usual amount 
of plasma (50 μΐ). The values were 5%-10% of normal and are supposed to be 
due to nonspecific stimulation as has been described for apoC-I and apoC-III 
in low concentrations.3 4 3 5 , 3 6 Furthermore, when increasing amounts of 
plasma up to 200 μΐ were added to the LPL activation assay, lipolysis did not 
further increase, whereas a linear increase was seen on the addition of normal 
plasma. However, other authors reported a total absence of activation5-7 
which can be explained by differences in assay conditions. 
Our patients also had extremely low postheparin LPL activity, which could 
not be enhanced by addition in the assay of increasing amounts of their own 
preheparin plasma and only to a small extent by normal plasma (Table 2). 
LPL was not increased using a high dose of heparin (100 U/kg bodyweight) in 
one subject, indicating maximal release of lipolytic activity already with use 
of 50 U heparin per kg. The influence of the fat content of the diet on the 
lipolytic activity has been pointed out,3 7 , 3 8 but LPL activity appeared to be 
independent of prior dietary fat intake in subject AV. Thus, a combination of 
apoC-II deficiency and very low postheparin LPL activity was present in 
these patients. The presence of inhibitors of LPL and hepatic lipase could be 
excluded in our patients. 
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This combined deficiency of apoC-II and LPL is the more striking, because in 
subjects with apoC-II deficiency very high LPL activity has been found,5,9 
whereas in patients with LPL deficiency a marked elevation of total plasma 
apoC-II has been reported,39 possibly as compensatory mechanisms in an 
attempt to achieve TG homeostasis. 
Infusion of two units of normal plasma in AV enhanced the clearance of 
plasma TG only to a limited extent; this is in contrast with the dramatic and 
sustained effect of (only one unit of) plasma in a patient with apoC-II 
deficiency described by Breckenridge et al.5 Apparently, supply of apoC-II in 
our patient resulted in an enhanced clearance of plasma TG only for a brief 
period as a consequence of the deficiency of LPL. 
Hepatic lipase was also decreased in our patients. This has also been reported 
for the patients with apoC-II deficiency,5,7 but is not common in LPL 
deficiency.·1"4" 
Besides the lack of apoprotein C-II, the propositi were also apoE-3 deficient. 
ApoE-3 deficiency has been suggested to represent the basic defect in 
predisposing to type III HLP.41 ApoE-3 deficiency was found in two other 
members of the family who were heterozygote for apoC-II deficiency and 
had normal plasma TG concentrations. So, apoE-3 deficiency does probably 
not play a role in the pathogenesis of the hyperlipoproteinemia in the 
propositi. After the infusion of plasma a temporary rise in the ratio VLDL-
cholesterol/VLDL-TG was observed, whereas LDL-cholesterol did not 
change. Apparently, VLDL-TG were catabolized for a brief period by 
mediation of LPL, leading to some accumulation of VLDL particles relati-
vely rich in cholesterol. The apoE-3 deficiency may have promoted this 
accumulation as in type III HLP.42 
In type I HLP there is an unexplained discrepancy between the concentration 
of chylomicrons-TG and VLDL-TG. Removal of chylomicrons is impai-
red,1,43,44 whereas VLDL-apoB turnover is not decreased.8,45 Apparently, in 
this form of HLP, VLDL are not cleared through the common removal 
mechanism for chylomicrons and VLDL.46 We have tried to estimate VLDL-
TG turnover rate during a 20% fat diet in one of the propositi with the 
combined LPL- and apoC-II deficiency. It should be emphasized that the 
kinetic data from this patient must be interpreted with some caution, since 
smaller chylomicron particles and chylomicron remnants were probably still 
present in the VLDL fraction. So, the VLDL-TG turnover measurement 
could have been influenced by some input of exogenous triglycerides. 
Despite this limitation, the data suggest at least that the removal of VLDL-
TG is not as severely impaired as that of chylomicrons-TG. Thus, VLDL 
catabolism appears to be independent of mediation by LPL and apoC-II. In 
addition, the extremely low LDL-cholesterol concentration suggests that 
VLDL is incompletely converted into LDL. 
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Nicoli and Lewis8 reported just recently also a normal VLDL-apoB synthetic 
rate in a patient with apoC-II deficiency. They found a normal conversion of 
VLDL-apoB to LDL-apoB. These authors suggested that hepatic lipase 
played a significant role in VLDL metabolism, since hepatic lipase activity 
against VLDL-TG in vitro was found to be normal. 
The plasma lipid concentrations of the family members were normal. The 
pedigree for apoC-II deficiency based on the apoC-II/C-HI ratio and LPL 
activation assay confirmed the findings by Cox et al6 that apoC-II deficiency 
is inherited as an autosomal recessive trait. The apoE-3 phenotype was based 
on the relative proportion of apoE-3.1 4 In contrast with our propositi, apoE-3 
was not deficient in the large kindred with apoC-II deficiency reported by 
Breckenridge et al.47 Segregation analysis of apoE-3 inheritance in our family 
agreed well with the postulated autosomal codominant inheritance for apoE-
З.
4 1
 In addition to the four propositi, two relatives were apoE-3 deficient 
(subjects 1-1 and II-8 in Fig. 5). In these subjects the ratio VLDL-cholesterol/ 
plasma TG was slightly elevated (0.68 and 0.65) as an indication for an 
increased amount of VLDL particles rich in cholesterol.48 The inheritance 
pattern for LPL deficiency could not be established exactly because of the 
overlap of LPL activity in heterozygotes and normals. The use of a higher 
dose of heparin, by which an additional release of lipolytic activity of 
approximately 20% can be obtained,19 might have helped in identifying 
heterozygotes, although no reliable test for the heterozygote carrier has been 
demonstrated so far.2 
In some members of the family thyroxine binding globulin deficiency has 
been found previously.10 Apparently, a fundamental defect exists in this 
family concerning the synthesis of several proteins, leading to this unique 
combination of deficiencies. 
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ALGEMENE SAMENVATTING 
In dit proefschrift worden studies beschreven die tot doel hebben meer 
inzicht te verkrijgen in de pathogenetische mechanismen van diverse vormen 
van hypertriglyceridemie. Triglyceriden worden in het bloed vervoerd in 
chylomicrons en very low density lipoproteïnen (VLDL). Chylomicrons 
bevatten triglyceriden afkomstig uit het dieetvet, terwijl VLDL triglyceriden 
transporteren van endogene oorsprong. 
In Hoofdstuk I wordt het normale lipoproteïnenmetabolisme in het kort 
besproken. Met name wordt daarbij de belangrijke rol aangeduid van de 
specifieke proteïnen van de lipoproteïnen, apoproteïnen genaamd. 
Bij hypertriglyceridemie is de concentratie in het bloed van VLDL en/of 
chylomicrons verhoogd, waarbij een verhoogde VLDL-spiegel (type IV 
hyperlipoproteïnemie) verreweg de meest frekwente vorm van hypertriglyce-
ridemie is. Dit is tevens een van de meest voorkomende vormen van 
hyperlipoproteïnemie in de westerse bevolking (rond 13% bij volwassen 
mannen en 4% bij volwassen vrouwen) en is frekwent geassocieerd met het 
optreden van hart- en vaatziekten. De rol van hypertriglyceridemie bij het 
ontstaan van voortijdige athérosclérose is overigens minder duidelijk dan die 
van hypercholesterolemie. Andere vormen van hypertriglyceridemie zoals 
type I en V hyperlipoproteïnemie worden klinisch gekenmerkt door perio-
dieke buikklachten, pancreatitis, eruptieve Xanthomen, lipemia retinalis en 
hepatosplenomegalie. Al deze vormen van hypertriglyceridemie kunnen 
primair (genetisch bepaald) zijn of secundair voorkomen bij bepaalde aan-
doeningen, waarvan diabetes mellitus en overmatig alcoholgebruik het meest 
frekwent zijn. 
In Hoofdstuk II worden verschillende methoden besproken, die in de litera-
tuur beschreven zijn om de produktiesnelheid van triglyceriden te meten. 
Hierbij wordt meestal gebruik gemaakt van radioactieve tracers, waarbij de 
VLDL gemerkt worden hetzij in het eiwit-deel (VLDL-apoB turnover rate) 
hetzij in het triglyceride-deel (VLDL-TG turnover rate). De eerste methode 
heeft als voordeel, dat behalve de VLDL-kinetiek ook de omzetting van 
VLDL naar IDL en LDL bestudeerd kan worden, omdat dit eiwit kwantita-
tief behouden blijft tijdens het proces van afsplitsing van triglyceriden. 
Wij hebben met beide methoden geëxperimenteerd, maar vanwege de 
relatieve eenvoud gekozen voor de radioglycerol-methode, waarbij de 
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VLDL-TG endogeen gelabeld worden, volgend op toediening van radioac-
tief gemerkt glycerol. 
Uit de vervalcurve van de specifieke activiteit van VLDL-TG worden de 
fractionele klaring en turnover rate berekend. De procedure en validiteit van 
deze methode worden uitvoerig besproken. Uit resultaten bij patiënten met 
primaire en secundaire vormen van type IV hyperlipoproteïnemie blijkt dat 
deze aandoening heterogeen is: zowel een overproduktie als ook een 
gestoorde afbraak kunnen ten grondslag liggen aan de hypertriglyceridemie. 
Bij de meerderheid blijkt overproduktie de oorzaak te zijn. 
Er worden twee verschillende monogenetische vormen van hypertriglyceri-
demie onderscheiden: familiaire hypertriglyceridemie, waarin patiënten 
voorkomen met alleen verhoogde VLDL-spiegels (type IV fenotype) en 
familiaire gecombineerde hyperlipidemie, waarin personen kunnen voorko-
men met verhoogde concentratie van VLDL (type IV fenotype), met ver-
hoogde concentratie van LDL (type Ha fenotype) en met verhoogde concen-
traties van zowel VLDL als LDL (type IIb fenotype). Patiënten met het type 
IV fenotype uit families met familiaire gecombineerde hyperlipoproteïnemie 
zouden volgens de literatuur een groter risico op hart- en vaatlijden hebben 
dan patiënten met hetzelfde fenotype uit families met familiaire hypertrigly-
ceridemie. In Hoofdstuk III wordt een studie beschreven van 45 type IV 
patiënten die genetisch geclassificeerd werden door familie-onderzoek. 
Daarbij kon geen verschil gevonden worden tussen beide groepen in: pro-
duktiesnelheid van triglyceriden, lipolytische activiteit in postheparineplasma 
en VLDL-apoC samenstelling. Het plasma HDL-cholesterolgehalte, dat 
negatief gecorreleerd is met de kans op hart- en vaatlijden, was in beide 
groepen even sterk verlaagd. Gemiddeld was de produktiesnelheid van 
triglyceriden in beide groepen verhoogd, maar het bleek dat de hypertrigly-
ceridemie bij een aantal personen (mede) werd veroorzaakt door een 
gestoorde afbraak. Dit kwam niet tot uiting in een verlaagde postheparine-
lipoproteïnelipase-activiteit. Het bleek dus niet mogelijk om familiaire 
gecombineerde hyperlipidemie te onderscheiden van familiaire hypertrigly-
ceridemie bij individuele patiënten met het type IV fenotype; bij patiënten 
met familiaire gecombineerde hyperlipidemie was de ratio LDL-/HDL-
cholesterol significant hoger dan bij normalen, in tegenstelling tot patiënten 
met familiaire hypertriglyceridemie en dit zou het verschil in kans op 
vroegtijdig hartlijden kunnen verklaren. 
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In Hoofdstuk IV wordt het onderzoek naar de Pathogenese van hypertrigly-
ceridemie bij type 2 (insuline-onafhankelijke) diabetes beschreven. Hierover 
wordt in de literatuur zeer verschillend gedacht. Enerzijds wordt als onder-
liggende oorzaak een verhoogde produktie van triglyceriden aangenomen, 
anderzijds wordt een gestoorde klaring door een tekort aan lipoproteïneli-
pase als primaire oorzaak gezien. Het is bekend dat hypertriglyceridemie 
gerelateerd is aan de mate van instelling van de diabetes, maar of dit ook 
geldt voor het plasma HDL-cholesterolgehalte, dat verlaagd is bij dit type 
patiënten, is nog onduidelijk. Voorts wordt hypertriglyceridemie vaak in 
verband gebracht met insuline, waarvan de concentratie door een toegeno-
men insulineresistentie bij deze patiënten veelal verhoogd is, hetgeen in de 
lever de synthese van triglyceriden zou bevorderen. 
De insulineresistentie, gemeten volgens de methode van Reaven et al, was 
gemiddeld bij onze patiënten verhoogd, maar er was een overlap met de 
controlegroep. De produktiesnelheid van de triglyceriden was eveneens 
verhoogd; deze bleek inderdaad samen te hangen met de mate van instelling 
en niet met de hoogte van de insulineconcentraties. Bij een deel van de 
patiënten werd de hypertriglyceridemie veroorzaakt door een gestoorde 
triglyceridenklaring. De lipoproteinelipase-activiteit viel echter binnen het 
normale bereik. Een gestoorde klaring moet dan berusten op een ander 
mechanisme dan een tekort aan dit enzym, zoals bijvoorbeeld een stoornis in 
de interaktie tussen enzym en substraat, of een stoornis in de opname van 
vetzuren in de cellen of de aanwezigheid van remmers van lipoproteïnelipase 
in het plasma. 
Behandeling met insuline gedurende een periode variërend van 3 tot 13 
weken, had uiteenlopende effecten op de kinetiek van plasmatriglyceriden. 
Er konden drie groepen worden onderscheiden: (1) patiënten bij wie de 
plasmatriglyceridenconcentratie daalde door daling in de produktiesnelheid. 
Bij deze groep was de instelling van de diabetes aanvankelijk slecht, maar 
deze verbeterde aanzienlijk tijdens de insulinetherapie; (2) patiënten bij wie 
de plasmatriglyceridenconccntratie daalde door een verbetering van de 
klaring. De instelling van de diabetes was bij de groep aanvankelijk minder 
slecht en de verbetering onder invloed van insuline was slechts gering; (3) 
patiënten bij wie geen daling van plasmatriglyceriden en produktiesnelheid 
optrad. In deze groep kwamen patiënten voor met een zeer hoog relatief 
lichaamsgewicht en met hoge insulinespiegels. 
In de hele groep van diabeten was het gemiddelde plasma HDL-cholesterol-
gehalte verlaagd en dit steeg niet onder invloed van insulinebehandeling. 
Geconcludeerd werd dat de Pathogenese van de hypertriglyceridemie bij 
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patiënten met type 2 diabetes heterogeen is en dat behandeling met insuline 
uiteenlopende effecten heeft op het triglyceridenmetabolisme. Het effect van 
insuline op het triglyceridengehalte is vooral goed bij patiënten met relatief 
hoge glucosespiegels. 
Hoofdstuk V vermeldt de resultaten van een onderzoek naar de VLDL-
apoC-samenstelling bij type 2-diabetespatiënten met hypertriglyceridemie. 
ApoC-II is de specifieke activator van lipoproteïnelipase. Een abnormale 
samenstelling van apoC zou de VLDL-partikels minder geschikt kunnen 
maken als substraat voor lipoproteïnelipase. Uit ons onderzoek blijkt, dat 
deze samenstelling niet afwijkt van die in een gezonde controlegroep en dus 
niet bijdraagt tot de Pathogenese van de hypertriglyceridemie bij deze 
patiënten. 
In Hoofdstuk VI worden twee patiënten beschreven met een zeer ernstige 
hypertriglyceridemie (type V hyperlipoproteïnemie): bij één patiënt als 
gevolg van alcoholmisbruik, bij de ander van diabetes mellitus (xanthomato-
sis diabeticorum). Tijdens behandeling was er een snelle daling in serumlipi-
den. Opmerkelijk was dat bij beide patiënten de lipoproteïnelipase-activiteit 
in postheparine-plasma niet verlaagd was. Wel werd bij beiden een abnor-
male apoproteïne C-samenstelling gevonden van de triglyceridenrijke lipo-
proteinen, hetgeen bijgedragen kan hebben tot het ontstaan van de massale 
hypertriglyceridemie. Tijdens de snelle daling in serumlipiden werd bij de 
patiënt met overmatig alcoholgebruik een tijdelijke ophoping gezien van 
VLDL-remnants, hetgeen kan samenhangen met het feit dat deze patiënt een 
relatieve apoE-3-deficiëntie vertoonde. Dit apoproteïne is blijkens dierexpe-
rimenteel onderzoek betrokken bij de binding aan receptoren en opname in 
de lever van deze remnants. 
In Hoofdstuk VII worden de pathofysiologische defecten beschreven bij 4 
patiënten uit één familie met familiaire hyperchylomicronemie (type I hyper-
lipoproteïnemie). Dit is een zeer zeldzame autosomaal recessieve aandoe-
ning, berustend op een tekort aan lipoproteïnelipase. Onlangs zijn enkele 
patiënten beschreven bij wie de hyperchylomicronemie berustte op een 
tekort aan de specifieke activator van lipoproteïnelipase, apoC-II; deze 
patiënten hadden een normale (latente) lipoproteïnelipase-activiteit. Bij 
onderzoek van onze patiënten bleek er een gecombineerde deficiëntie te 
bestaan van zowel apoC-II als lipoproteïnelipase. In tegenstelling tot eerder 
beschreven patiënten met apoC-II-deficiëntie had toediening van normaal 
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plasma (met daarin apoC-II) aan één van onze patiënten slechts een zeer 
gering effekt op het triglyceridengehalte van het plasma. Blijkbaar werd na 
toediening van de ontbrekende specifieke activator het tekort aan het enzym 
lipoproteïnelipase de beperkende factor voor de eliminatie van chylomi-
crons. Bij dezelfde patiënte werd ook de omzetsnelhcid van VLDL gemeten 
en deze bleek niet verlaagd te zijn. Hoe VLDL bij deze patiënten dan wel 
geklaard worden blijft nog een vraag, want onder normale omstandigheden 
worden VLDL en chylomicrons door hetzelfde klaringsmechanisme uit het 
plasma verwijderd. 
De plasmalipidenconcentraties waren normaal bij alle overige leden van de 
familie van de patiënten. De autosomaal recessieve wijze van overerving van 
de apoC-II-deficiëntie kon worden bevestigd. De wijze van overerving van 
lipoproteïnelipase-deficiëntie was niet goed te onderzoeken tengevolge van 
de overlap in lipoproteïnelipase-activiteit tussen heterozygoten en normalen. 
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STELLINGEN 
Behorende bij het proefschrift 
METABOLIC STUDIES IN VARIOUS FORMS 
OF HYPERTRIGLYCERIDEMIA IN MAN 
In het openbaar te verdedigen 
op vrijdag 2 april 1982 
des namiddags te 2 uur 
door 
A.F.H. Stalenhoef 
I 
De synthesesnelheid van very low density lipoproteinen bij patiënten 
met type 2 (insuline-onafhankelijke) diabetes hangt samen met de 
mate van instelling van de diabetes en niet met de hoogte van de 
insulinespiegels in het bloed. 
- dit proefschrift 
II 
Een gestoorde klaring van very low density lipoproteinen bij patiënten 
met type 2 (insuline-onafhankelijke) diabetes kan niet worden ver-
klaard door een tekort aan lipoproteinelipase-activiteit of een veran-
derde samenstelling van apoproteine С van de very low density lipo­
proteinen. 
- dit proefschrift 
III 
Bij patiënten met type I hyperlipoproteinemie worden very low density 
lipoproteinen normaal omgezet zonder tussenkomst van apoproteïne 
C-II en lipoproteinelipase. 
- dit proefschrift 
IV 
Het bewijs voor een directe beschermende rol van high density lipo-
proteinen bij de ontwikkeling van athérosclérose ontbreekt. Mogelijk 
is een hoge concentratie van deze lipoproteinen slechts een uiting van 
een effectieve lipolysis van triglyceride-rijke lipoproteinen met snelle 
verdwijning uit het plasma van atherogene remnant-partikels. 
- Nikkila EA. Eur J Clin Invest 8:111-113, 1978 
V 
De electroforese van het serum, gevolgd door een lipofiele kleuring 
zoals die in de meeste klinisch-chemische laboratoria wordt toegepast, 
heeft geen waarde voor de differentiaal diagnostiek van hyperlipopro-
teinemieén. 
VI 
Bij patiënten met familiaire hypercholesterolemie, die onvoldoende 
reageren op medicamenteuze therapie of die deze niet kunnen verdra-
gen, dient een partiele ileale bypass operatie overwogen te worden 
- Spengel FA et al Lancet, 11, 768-770, 1981 
VII 
Bij een patient, die zich presenteert met een idiopathische trombocyto-
penibche purpura, dient de diagnose sarcoidosis mede overwogen te 
worden 
- Dickerman MD et al J Paedtat 81 758-764, 1972 
- eigen waarneming 
VIII 
De preoperatieve hartcathetensatie bij patiënten, die voor vervanging 
van een hartklep in aanmerking komen, dient dankzij de ontwikkeling 
van de echocardiografie met meer routinematig te geschieden 
- St John Sutton MG et al New Engl J Med 305 1231-1238, 1981 
IX 
Aangezien digoxine door de gastrointestinale flora ten dele omgezet 
kan worden in onwerkzame metabolieten, dient men bij toediening van 
antibiotica aan patiënten, die digoxine gebruiken, bedacht te zijn op de 
ontwikkeling van een digitahs-intoxicatie 
- Lmdenbaum J et al New Engl J Med 305 789-794, 1981 
X 
Replicatie van het hepatitis В virus vindt met uitsluitend in de lever 
plaats, maar ook in de alvleesklier. 
- Shimoda Τ et al Gastroenterology 81 989-1005, 1981 
XI 
Het is met waarschijnlijk, dat de invoering van het basisexamen interne 
geneeskunde voor assistenten de kwaliteit van de Nederlandse internist 
zal verhogen 
XII 
Het verdient aanbeveling om in het voortgezet onderwijs de Franse 
taal als keuzevak verplicht te stellen 
XIII 
Het ware te wensen, dat de stelregel van de redacteur van de New 
England Journal of Medicine om manuscripten, waaruit reeds delen in 
de lekenpers zijn verschenen, af te wijzen, ook door redacties van 
andere medische tijdschriften als gedragslijn zou worden gevolgd 
XIV 
Gezien het gunstig effekt van lichamelijke inspanning op het HDL-
cholesterolgehalte dient het gezegde "hardlopers zijn doodlopers" 
vooral m overdrachtelijke zin te worden opgevat 
XV 
Het valt te overwegen om voor politici en ambtsdragers wettelijk een 
maximum leeftijd vast te stellen, tot welke fouten in het verleden 
begaan nog dis jeugdzonden beschouwd kunnen worden 


